var title_f32_40_33408="Cytotoxicity assays III";
var content_f32_40_33408=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Flow cytometry based cytotoxicity assay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 236px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upregulation of LAMP-1/CD107a on NK cells as an indicator of granular exocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33408=[""].join("\n");
var outline_f32_40_33408=null;
var title_f32_40_33409="Newborn testicular torsion";
var content_f32_40_33409=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Neonatal testicular torsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a newborn male, a clinical diagnosis of prenatal testicular torsion was made based upon the physical finding of a firm, enlarged, non-tender right testicle prenatal torsion. Surgical exploration through an inguinal incision confirmed extravaginal testicular torsion and an ischemic testicle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence S. Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33409=[""].join("\n");
var outline_f32_40_33409=null;
var title_f32_40_33410="Perleche";
var content_f32_40_33410=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Perl&egrave;che",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perl&egrave;che (angular cheilitis). This patient has scaling, fissuring, and crusting at the corners of her mouth. She has atopic dermatitis elsewhere on her skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33410=[""].join("\n");
var outline_f32_40_33410=null;
var title_f32_40_33411="Patient information: Vaginal cancer (The Basics)";
var content_f32_40_33411=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83806\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/57/32658\">",
"          Radical hysterectomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/35/24114\">",
"         Patient information: Brachytherapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/32/28163\">",
"         Patient information: Cervical cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/27/40370\">",
"         Patient information: Menopause (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/8/15491\">",
"         Patient information: Pap tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/18/12579\">",
"         Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/48/6914\">",
"         Patient information: Colposcopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vaginal cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vaginal-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1670209043\">",
"      <span class=\"h1\">",
"       What is vaginal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vaginal cancer happens when normal cells in the vagina change into abnormal cells and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). There are different types of vaginal cancer, depending on the cells involved.",
"     </p>",
"     <p>",
"      This article discusses cancer that starts in the vagina. But women can also get cancer in the vagina after cancer from another part of the body spreads to the vagina.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209075\">",
"      <span class=\"h1\">",
"       What are the symptoms of vaginal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some women with vaginal cancer have no symptoms. They find out they have it when their doctor or nurse does a routine Pap test to check for cancer of the cervix (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). During a Pap test, a doctor or nurse places a metal or plastic device called a &ldquo;speculum&rdquo; in the vagina. The speculum holds the walls of the vagina open, so that the doctor or nurse can see the cervix. Then he or she uses a small brush to collect cells from the cervix.",
"     </p>",
"     <p>",
"      When vaginal cancer causes symptoms, the most common symptom is abnormal bleeding from the vagina. The bleeding usually happens after sex or in women who have already gone through menopause. Menopause is the time in a woman&rsquo;s life when she stops having her monthly periods.",
"     </p>",
"     <p>",
"      Other symptoms of vaginal cancer can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fluid coming out of the vagina that is watery, bloody, or bad-smelling",
"       </li>",
"       <li>",
"        Pain when urinating, blood in the urine, or feeling the need to urinate often",
"       </li>",
"       <li>",
"        Trouble having bowel movements, black-colored bowel movements, or feeling the need to have a bowel movement when your bowels are empty",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not vaginal cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209107\">",
"      <span class=\"h1\">",
"       Is there a test for vaginal cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for vaginal cancer, your doctor or nurse will do a pelvic exam. He or she might use a special magnifying lens called a &ldquo;colposcope&rdquo; to see the vagina more clearly.",
"     </p>",
"     <p>",
"      During the exam, he or she will do a test called a biopsy. This involves taking a small sample of tissue from the area that looks like cancer. Then another doctor will look at the sample under a microscope.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209122\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209137\">",
"      <span class=\"h1\">",
"       How is vaginal cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The right treatment for you will depend a lot on the stage of your cancer, how big the cancer is, and where it is in your vagina. Your treatment will also depend on your age, other medical problems, and whether you might want to get pregnant in the future.",
"     </p>",
"     <p>",
"      Treatment for vaginal cancer includes 1 or more of following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; Vaginal cancer is usually treated with surgery to remove the uterus, cervix, and upper part of the vagina. This is called a &ldquo;radical hysterectomy&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef78941 \" href=\"mobipreview.htm?31/57/32658\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells. Sometimes, the radiation comes from a machine that is outside the body. Other times, the radiation comes from tiny seeds or capsules that are put in the body, near the cancer.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209175\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow-up tests usually include pelvic exams and tests (similar to Pap tests) to check the cells in the vagina for cancer.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your vaginal cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209190\">",
"      <span class=\"h1\">",
"       What happens if my vaginal cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your vaginal cancer comes back or spreads, you might have more surgery or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209205\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant in the future?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have not yet gone through menopause and want to have a baby in the future, talk with your doctor before starting treatment. Some women can still get pregnant after being treated for vaginal cancer. But a woman can&rsquo;t get pregnant after some types of treatment, such as a hysterectomy, radiation therapy, or some types of chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209220\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for vaginal cancer involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1670209235\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/8/15491?source=see_link\">",
"       Patient information: Pap tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=see_link\">",
"       Patient information: Menopause (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28163?source=see_link\">",
"       Patient information: Cervical cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/35/24114?source=see_link\">",
"       Patient information: Brachytherapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=see_link\">",
"       Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/48/6914?source=see_link\">",
"       Patient information: Colposcopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/40/33411?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83806 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33411=[""].join("\n");
var outline_f32_40_33411=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209043\">",
"      What is vaginal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209075\">",
"      What are the symptoms of vaginal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209107\">",
"      Is there a test for vaginal cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209122\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209137\">",
"      How is vaginal cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209175\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209190\">",
"      What happens if my vaginal cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209205\">",
"      What if I want to get pregnant in the future?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209220\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1670209235\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83806\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/57/32658\">",
"       Radical hysterectomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/35/24114?source=related_link\">",
"      Patient information: Brachytherapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/32/28163?source=related_link\">",
"      Patient information: Cervical cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/48/6914?source=related_link\">",
"      Patient information: Colposcopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/8/15491?source=related_link\">",
"      Patient information: Pap tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/18/12579?source=related_link\">",
"      Patient information: Preserving fertility after cancer treatment in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33412="Chlordiazepoxide: Patient drug information";
var content_f32_40_33412=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlordiazepoxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4679?source=see_link\">",
"     see \"Chlordiazepoxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F11263328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691707",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat alcohol withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm you before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701767",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlordiazepoxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694577",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Capsules may be opened and contents mixed with food or liquid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect capsules from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11598 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33412=[""].join("\n");
var outline_f32_40_33412=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11263328\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017055\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017054\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017059\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017060\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017062\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017057\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017058\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017063\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017064\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4679?source=related_link\">",
"      Chlordiazepoxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33413="Ranibizumab: Drug information";
var content_f32_40_33413=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ranibizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/10/30883?source=see_link\">",
"    see \"Ranibizumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3025066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lucentis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5376866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lucentis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3025070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiogenesis Inhibitor;",
"     </li>",
"     <li>",
"      Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Ophthalmic Agent;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3025114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Age-related macular degeneration (AMD):",
"     </b>",
"     Intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     0.5 mg once a month. Frequency may be reduced (eg, 4-5 injections over 9 months) after the first 3 injections or may be reduced after the first 4 injections to once every 3 months if monthly injections are not feasible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     0.5 mg once a month. Frequency may be reduced after the first 3 injections to once every 3 months if monthly injections are not feasible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A regimen averaging 4-5 doses over 9 months is expected to maintain visual acuity and an every-3-month dosing regimen has reportedly resulted in a ~5 letter (1 line) loss of visual acuity over 9 months, as compared to monthly dosing which may result in an additional ~1-2 letter gain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic macular edema (DME):",
"     </b>",
"     Intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     0.3 mg once a month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     0.5 mg once a month until achievement of stable visual acuity for 3 consecutive months. Upon discontinuation, may resume monthly therapy if monitoring identifies a loss of visual acuity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Macular edema following retinal vein occlusion (RVO):",
"     </b>",
"     Intravitreal: 0.5 mg once a month.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends continuing therapy until achievement of stable visual acuity for 3 consecutive months; upon discontinuation, may resume monthly therapy if monitoring identifies a loss of visual acuity.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3025115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3025116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3025117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3025123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lucentis&reg;: 0.3 mg/0.05 mL (0.05 mL) [6 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lucentis&reg;: 0.5 mg/0.05 mL (0.05 mL) [10 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5950141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lucentis&reg;: 10 mg/mL (0.3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3025068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3025118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     For ophthalmic intravitreal injection only. Remove contents from vial using a 5 micron 19-gauge filter needle attached to a tuberculin syringe. Discard filter needle and replace with a sterile 30 gauge",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch needle for injection (do not use filter needle for intravitreal injection). Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Canadian labeling recommends administering ranibizumab at least 30 minutes after laser photocoagulation therapy when administered on the same day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3030717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of neovascular (wet) age-related macular degeneration (AMD); treatment of macular edema following retinal vein occlusion (RVO); diabetic macular edema (DME)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15241855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ranibizumab may be confused with bevacizumab",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3025080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rates of ocular adverse reactions reported for control group when percentages overlapped with treatment group.",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     <b>",
"      As reported with AMD, RVO, and DME studies:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolic events (AMD trials during first year: 2%; control: 1%; DME trials at 3 years: 11%; control rate not given)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctival hemorrhage (48% to 74%; control: 32% to 60%), eye pain (17% to 35%; control 12% to 30%), vitreous floaters (7% to 27%), intraocular pressure increased (7% to 24%), blurred vision/visual disturbance (5% to 18%), intraocular inflammation (1% to 18%; control 3% to 8%), foreign body sensation (7% to 16%; control: 5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Cataract, blepharitis, dry eye, eye irritation, lacrimation increased, maculopathy, ocular hyperemia, pruritus, and vitreous detachment occurred in &gt;10% of patients, but also occurred either in similar percentages to the control or more often in the control in some studies.",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Stroke (AMD trials during 2 years: 3%; control: 1%; DME trials at 3 years: 2%; control rate not given)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal degeneration (1% to 8%), injection site hemorrhage (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Conjunctival hyperemia, ocular discomfort, posterior capsule opacification, and retinal disorder occurred in 1% to 10% of patients, but also occurred in similar percentages to the control or more often in the control in some of the studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Ranibizumab antibodies (1% to 8%), influenza (3% to 7%; control: 2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All indications:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Anterior chamber inflammation, anxiety, back pain, corneal edema, corneal epithelium defect, corneal erosion, coronary artery occlusion, dizziness, endophthalmitis, eyelid pain, hypoglycemia, iatrogenic traumatic cataracts, intestinal obstruction, lid margin discharge, photophobia, retinal pigment epithelium tear, rhegmatogenous retinal detachments, rhinorrhea,  urticaria, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3025075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to ranibizumab or any component of the formulation; ocular or periocular infection",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Active intraocular inflammation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3025076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should be used. Patients should be monitored for potential infection following the injection and instructed to report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity may present as severe intraocular inflammation; instruct patients to report intraocular inflammation that increases with severity. Rare hypersensitivity reactions (including anaphylaxis) have been associated with another VEGF inhibitor, pegaptanib, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Prior to and following intravitreal injection, intraocular pressure may increase. Onset postinjection is seen within 60 minutes. Monitor intraocular pressure before and after injection and manage accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events: Risk of thromboembolic events, particularly stroke, may be increased following intravitreal administration of VEGF inhibitors. Use caution in patients with known risk factors (eg, history of stroke, TIA)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Intravitreal injections of ranibizumab may induce temporary visual disturbances that impair the ability to drive or operate machinery. Affected patients should be advised to abstain from driving or using machinery until resolution of visual disturbances.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetic macular edema (DME): Pooled analysis of trials involving DME patients revealed a higher incidence of fatal events in DME patients treated with ranibizumab compared to control (3% in patients treated with 0.3 mg in the first 2 years compared to 1% in the control). Overall, the incidence of fatalities was consistent with deaths normally observed in patients with advanced diabetic complications; however, a potential association between fatal events and intravitreal administration of VEGF inhibitors cannot be excluded.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3025071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3025072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse fetal effects have been observed in some animal reproduction studies. Based on its mechanism of action, adverse effects on pregnancy would be expected. Canadian labeling recommends that women of childbearing potential use effective contraception during therapy and to wait 3 months after therapy before trying to conceive.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3025074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lucentis Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/0.05 mL (0.05 mL): $1404.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/0.05 mL (0.05 mL): $2437.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3025120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Intraocular pressure (prior to and  30 minutes following injection via tonometry); consider checking for perfusion of the optic nerve head immediately following injection; signs of infection/inflammation (for first week following injection); retinal perfusion, endophthalmitis; visual acuity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5378700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lucentis (AR, AT, AU, BE, BR, CH, CN, CO, CZ, DE, DK, EC, EE, ES, FR, GB, GR, HK, ID, IE, IL, IT, KP, MY, NO, NZ, PE, PH, PL, PT, RU, SE, SG, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3025108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ranibizumab is a recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3025110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Low levels are detected in the serum following intravitreal injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Vitreous: ~9 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gaudreault J, Fei D, Rusit J, et al, &ldquo;Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration,&rdquo;",
"      <i>",
"       Invest Ophthalmol Vis Sci",
"      </i>",
"      , 2005, 46(2):726-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/40/33413/abstract-text/15671306/pubmed\" id=\"15671306\" target=\"_blank\">",
"        15671306",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heier JS, Antoszyk AN, Pavan PR, et al, &ldquo;Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose Study,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2006,  113(4):633-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Massin P, Bandello F, Garweg JG, et al, &ldquo;Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-Month, Randomized, Controlled, Double-Masked, Multicenter Phase II Study,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2010, 33(11):2399-405.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/40/33413/abstract-text/20980427/pubmed\" id=\"20980427\" target=\"_blank\">",
"        20980427",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell P, Bandello F, Schmidt-Erfurth U, et al, &ldquo;The RESTORE STUDY: Ranibizumab Monotherapy or Combined With Laser versus Laser Monotherapy for Diabetic Macular Edema,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2011, 118(4):615-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/40/33413/abstract-text/21459215/pubmed\" id=\"21459215\" target=\"_blank\">",
"        21459215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenfeld PJ, Brown DM, Heier JS, et al, &ldquo;Ranibizumab for Neovascular Age-Related Macular Degeneration,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(14):1419-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/40/33413/abstract-text/17021318/pubmed\" id=\"17021318\" target=\"_blank\">",
"        17021318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenfeld PJ, Rich RM and Lalwani, &ldquo;Ranibizumab: Phase III Clinical Trial Results,&rdquo;",
"      <i>",
"       Ophthalmol Clin North Am",
"      </i>",
"      , 2006, 19(3):361-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/40/33413/abstract-text/16935211/pubmed\" id=\"16935211\" target=\"_blank\">",
"        16935211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10337 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33413=[""].join("\n");
var outline_f32_40_33413=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025066\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5376866\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025070\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025114\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025115\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025116\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025117\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025123\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5950141\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025068\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025118\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3030717\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241855\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025080\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025075\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025076\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299982\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222715\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025071\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025072\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025074\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322947\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025120\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5378700\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025108\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025110\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10337|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/10/30883?source=related_link\">",
"      Ranibizumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33414="RBC membrane protein mutations";
var content_f32_40_33414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    RBC membrane protein mutations in hereditary spherocytosis, hereditary elliptocytosis, and hereditary pyropoikilocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The domain structure of these proteins is shown, with positions of known mutations causing hereditary spherocytosis (HS) and hereditary elliptocytosis/hereditary pyropoikilocytosis (HE/HPP) indicated beneath each protein.",
"    <br>",
"     (B) The structure of the spectrin tetramer is shown, illustrating the triple helical coiled-coil repeats of the spectrin peptides, the head-to-head spectrin self-association sites, and the nucleation sites that initiate the side-to-side interaction between alpha and beta spectrin chains.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Tse WT, Lux SE. Red blood cell membrane disorders. Br J Haematol 1999; 104:2. Copyright 1999 Blackwell Science.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33414=[""].join("\n");
var outline_f32_40_33414=null;
var title_f32_40_33415="Anticoagulant and antiplatelet therapy in patients with infective endocarditis";
var content_f32_40_33415=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant and antiplatelet therapy in patients with infective endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Thomas L Ortel, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33415/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/40/33415/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulants were first used in patients with infective endocarditis (IE) over 60 years ago. Subsequently, several investigators reported that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    when combined with penicillin in the treatment of patients with IE was associated with a high incidence of hemorrhagic stroke. By the mid-1950s, most experts had concluded that the use of anticoagulants in patients with IE was excessively dangerous, and that its routine use should be abandoned.",
"   </p>",
"   <p>",
"    However, an increasing proportion of patients with IE have infected prosthetic cardiac valves, many of whom require long-term anticoagulation therapy to prevent valve dysfunction. The therapeutic dilemma in the management of such patients is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuing anticoagulant therapy in the face of a prosthetic valvular infection poses the risk of hemorrhagic transformation of an embolic stroke or accentuation of bleeding from septic arteritis or mycotic aneurysms should they occur.",
"     </li>",
"     <li>",
"      Stopping anticoagulant therapy introduces the risk of clots forming on the prosthetic valve, leading to the risk of further emboli or prosthetic value thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of anticoagulation in patients with IE will be reviewed here. It should be emphasized that our recommendations and those included in published guidelines for the use of anticoagulation therapy in IE are primarily based on older studies, anecdotal evidence, and expert opinion. Thus, these recommendations use extrapolation of general medical principles and available information, rather than randomized controlled trials to reach conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Overall discussions of the treatment and complications of prosthetic valve endocarditis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT AND DISEASE RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not uncommon for patients with IE to suffer an embolic stroke before the initiation of any form of therapy or within a few days following the diagnosis of IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3\">",
"     3",
"    </a>",
"    ]. In such cases, clinicians are faced with the dual problem of treating a patient with IE and an acute or subacute stroke. In addition to producing cerebral infarction, infected emboli can rarely cause septic cranial arteritis, mycotic aneurysms, and brain abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk of embolic stroke in IE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of echocardiography to identify patients with IE at risk for embolism is low for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 90 percent of patients with IE have valvular vegetations detectable by transesophageal echocardiography.",
"     </li>",
"     <li>",
"      Approximately 15 to 35 percent of all patients with IE develop clinically evident systemic emboli. If more sensitive tests such as magnetic resonance imaging are used, a much higher proportion of patients with IE have evidence of emboli. As an example, in one prospective study of 65 patients with left-sided endocarditis, 35 percent of patients had evidence of a symptomatic cerebrovascular complication; another 30 percent had clinically &ldquo;silent&rdquo; evidence of a cerebrovascular complication using magnetic resonance imaging of the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, the presence of a vegetation detected by echocardiography has little utility in assessing the",
"    <strong>",
"     actual",
"    </strong>",
"    risk that this vegetation will result in embolism. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Role of TEE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even though the presence of vegetations by echocardiography is not particularly useful in predicting the risk of embolism in an individual patient, the following risk factors have been suggested as useful indicators of a higher than normal risk of embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18249?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications and outcome of infective endocarditis\", section on 'Predictors of embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Size of vegetation &gt;10 mm",
"     </li>",
"     <li>",
"      Vegetation location on aortic or mitral valve, especially the anterior mitral leaflet",
"     </li>",
"     <li>",
"      Virulent organisms (eg, S. aureus)",
"     </li>",
"     <li>",
"      Visibility of the vegetation(s) on TTE and TEE rather than only on TEE",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this list may be useful in assessing embolic risk in population-based studies, its utility in making decisions in an individual patient is limited. In addition, the results of some studies assessing the beneficial effect of anticoagulation in patients with IE are contradictory. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One prospective cohort study of 175 patients with IE due to S. aureus concluded that patients receiving anticoagulation at the time of admission for IE were significantly less likely to have experienced a major cerebral event at the time of admission compared with those without anticoagulation (15 versus 37 percent; adjusted OR 0.27; 95% CI 0.075-0.96) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/7\">",
"       7",
"      </a>",
"      ]. The decrease was primarily due to a decrease in cerebral thromboembolic episodes in those patients on anticoagulant therapy.",
"     </li>",
"     <li>",
"      A randomized, placebo-controlled study has shown that anti-platelet therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      had no effect on the risk of stroke in patients with IE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study has shown that patients with IE due to S. aureus had an increased risk of stroke if they were concurrently receiving anticoagulants, although this was primarily due to hemorrhagic rather than thromboembolic stroke (discussed below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Native valve IE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that prophylactic anticoagulation reduces the incidence of emboli in patients with native valve IE. As a result, the 2012 ACCP Guidelines recommend against routine anticoagulant therapy (Grade 1C) and against routine antiplatelet therapy (Grade 1B), unless a separate indication exists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, there are compelling data to suggest that prompt use of antibiotics significantly reduces the incidence of emboli in patients with IE. This was illustrated in a report of patients with native valve IE, in whom the rate of embolization fell from 5 to 13 per 1000 patient days during the first week of antibiotic therapy to 1.2 to 1.7 per 1000 patient days after two weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Similar findings were noted in another large case series in which a prompt reduction in emboli was seen shortly after antibiotic therapy was initiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18249?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications and outcome of infective endocarditis\", section on 'Effect of antibiotic therapy on embolic risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Prosthetic valve IE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of patients with bioprosthetic valves who are in normal sinus rhythm, patients with prosthetic heart valves have an increased risk of thromboembolism that can be markedly reduced with appropriate anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=see_link&amp;anchor=H14#H14\">",
"     \"Complications of prosthetic heart valves\", section on 'Systemic embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with prosthetic valve IE have the same risk of cerebral emboli as other patients with IE. There is conflicting evidence on the effectiveness of anticoagulation in reducing this risk of embolization, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 52 patients with prosthetic valve IE, central nervous system embolic events occurred less frequently in patients who received adequate anticoagulation (3 of 38 versus 10 of 14, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/13\">",
"       13",
"      </a>",
"      ]. A suggestion of similar benefit from anticoagulation was also noted in another series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, anticoagulation either failed to reduce the incidence of emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3,15\">",
"       3,15",
"      </a>",
"      ] or was associated with a higher risk of serious CNS bleeding in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/4,16,17\">",
"       4,16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As is the case with native valve IE, prompt antibiotic treatment appears to be more important in preventing neurologic complications in patients with prosthetic valve IE than anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mechanisms of intracerebral hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three potential mechanisms exist for intracerebral hemorrhage in patients with IE:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic transformation of an ischemic infarct",
"     </li>",
"     <li>",
"      Septic erosion of arteritic vessels without aneurysm formation",
"     </li>",
"     <li>",
"      Rupture of mycotic aneurysms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemorrhagic transformation and septic arteritis are more common causes of intracerebral hemorrhage associated with IE than mycotic aneurysm rupture. The latter is relatively uncommon in the modern era of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Rupture of mycotic aneurysms typically causes intraparenchymal hemorrhage, but limited subarachnoid hemorrhage can also occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Septic arteritis without aneurysm, when present, typically occurs in the small cortical arterial branches located in the spaces of cortical sulci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/19\">",
"     19",
"    </a>",
"    ], and thus is generally invisible with CT or MR angiographic imaging. The appearance of arteritis is nonspecific at best and undetectable in many cases, even when conventional angiography is used. Thus, it is not surprising that no studies have evaluated the optimal treatment of septic arteritis in patients with IE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hazards of anticoagulation were outlined in a study of 35 patients with native valve left-sided S. aureus IE and 21 patients with S. aureus left-sided prosthetic valve IE. &nbsp;None of the 35 patients with native-valve IE was receiving anticoagulants at the time of diagnosis; in contrast, 19 of 21 patients with prosthetic valve IE were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy at the time of diagnosis. Although the INR was not reported for these patients, the prothrombin time data suggested that they were not excessively anticoagulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    was substituted for warfarin during the hospitalization of these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/9\">",
"     9",
"    </a>",
"    ]. The incidence of embolic episodes, including all major neurologic complications, was comparable in patients with native valve IE and patients with prosthetic valve IE (63 versus 67 percent). However, 6 of 12 patients with neurologic complications and concurrent prosthetic valve IE developed hemorrhagic brain lesions, all of whom died. In contrast, only one patient in the nonanticoagulated native valve group developed hemorrhagic transformation of a presumed embolic stroke.",
"   </p>",
"   <p>",
"    These findings led the authors to conclude that the incidence of hemorrhagic transformation of embolic strokes was so high in patients with prosthetic valve S. aureus IE that anticoagulation therapy should be discontinued until the septic phase of the disease is overcome.",
"   </p>",
"   <p>",
"    In contrast, another study found that anticoagulant therapy was not associated with an increased risk for cerebral hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/7\">",
"     7",
"    </a>",
"    ]. Out of 175 consecutive patients with S. aureus aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral valve IE patients, 40 were on anticoagulant therapy at the time of admission. Out of a total of four patients sustaining a hemorrhagic stroke at the time of admission, none was on anticoagulant therapy. One additional patient was diagnosed with cerebral hemorrhage during the course of hospitalization; this patient was on anticoagulation at the time of the event. These authors concluded that anticoagulation did not increase the risk of cerebral hemorrhage in S. aureus IE, and that it should be continued when clinically indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use of aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of a few small studies have suggested that the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    might attenuate the virulence of S. aureus infections and reduce the frequency of embolic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Similarly, a large retrospective study found a reduced embolic risk among patients who received daily antiplatelet therapy before the onset of IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, no benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was seen in a randomized trial involving 115 patients with IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/8\">",
"     8",
"    </a>",
"    ]. The rate of embolic events was not significantly different in patients treated with aspirin compared with those receiving placebo (28 versus 20 percent with placebo, odds ratio 1.6; 95% CI 0.68-3.9). There was a trend toward a higher incidence of bleeding in patients taking aspirin (odds ratio 1.9; 95% CI 0.76-4.9). However, there were no differences between the two groups in the development of new intracranial lesions, vegetation resolution, or valvular dysfunction. Concomitant use of systemic anticoagulation by 23 percent of the patients was a potentially important limitation of this study; most of the patients receiving anticoagulants had prosthetic heart valves.",
"   </p>",
"   <p>",
"    Patients had been symptomatic for approximately one month before the diagnosis of IE and the subsequent use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/8\">",
"     8",
"    </a>",
"    ]. In fact, aspirin might have been more effective in reducing embolic events if it had been started earlier in the course of IE. This supposition was examined in a retrospective analysis of data from the 84 patients ineligible for the randomized study because they were taking long-term aspirin (average daily dose 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    prior to the diagnosis of IE. Results of this analysis included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of embolism in 84 patients taking long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      before the onset of IE as well as throughout the four-week observation period (21 percent) was similar to that seen in 55 patients randomly assigned to treatment with placebo (20 percent, unadjusted odds ratio 0.80; 95% CI 0.36-1.8).",
"     </li>",
"     <li>",
"      As also noted in the randomized study, there was a trend toward excess bleeding in long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      recipients compared with those receiving placebo (unadjusted odds ratio 2.3; 95% CI 0.97-5.7).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of this study concluded that the need for continuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    should be carefully assessed in patients with a diagnosis of IE who are already taking aspirin. The risk versus benefit of continuing or discontinuing aspirin should be carefully weighed in order to minimize the potential risk of bleeding during the acute phase of IE, should aspirin be continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the findings of the single randomized trial discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/8\">",
"     8",
"    </a>",
"    ], we and others do not recommend routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to prevent embolism in patients with IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mechanical heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong consensus among experts regarding the decision to continue or temporarily discontinue anticoagulation when IE develops in patients already receiving anticoagulation for mechanical heart valves. Two divergent approaches have been recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Continue anticoagulation unless the patient develops a stroke",
"      </strong>",
"      &mdash; The rationale for this approach is based upon studies reporting a decreased rate of neurologic complications with adequate anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/13,14\">",
"       13,14",
"      </a>",
"      ], as well as the well-known high risk of thrombosis of the mechanical valve if anticoagulation is stopped. Many experts believe that long-term anticoagulation therapy can be safely and appropriately continued in patients with prosthetic valve IE if there is no evidence of a CNS complication consistent with emboli. If anticoagulation is continued, some experts recommend converting from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in order to achieve better control of anticoagulation during the active phase of infective endocarditis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Patients with stroke'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Temporarily discontinue anticoagulation",
"      </strong>",
"      &mdash; The rationale for this approach is based upon observational evidence from a single study suggesting an appreciable risk of fatal brain hemorrhage in patients with mechanical heart valves and left-sided S. aureus IE who are continued on anticoagulant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/9\">",
"       9",
"      </a>",
"      ]. Discontinuing anticoagulation until blood cultures are negative and the clinical signs of active infection or ongoing sepsis have resolved is a reasonable approach in such patients. However, this position is not universally held and there are no studies to guide the physician concerning the safest time to resume anticoagulation if this option is chosen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 ACCP Guidelines suggest that the vitamin K antagonist (VKA) should be discontinued in patients with an infected prosthetic valve who are taking the VKA at the time of initial presentation, until it is clear that invasive procedures will not be required and the patient has stabilized without signs of central nervous system involvement (eg, intracranial bleeding due to a ruptured mycotic aneurysm or hemorrhagic transformation of a bland infarct). VKA therapy can be reinstituted when the patient is deemed stable without contraindications or neurologic complications (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Patients with stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation should be temporarily discontinued in all patients with a mechanical valve and IE who develop central nervous system symptoms compatible with embolism or stroke, despite the potential risk of further thromboembolism from their prosthetic heart valves. Anticoagulant therapy is contraindicated if there is any evidence on imaging studies of hemorrhagic transformation of the stroke.",
"   </p>",
"   <p>",
"    However, there are no studies that give guidance as to the best form of brain imaging to use in order to detect hemorrhagic transformation, nor are there published criteria that help determine when reinstitution of anticoagulation therapy will be safe after a stroke.",
"   </p>",
"   <p>",
"    The optimal time to restart anticoagulation after stroke in patients with IE and mechanical heart valves is unknown. Some guidance may be found from data collected from patients without IE or hypertension who have an embolic stroke. If there is no evidence for hemorrhage on CT scan one to two days following the stroke, anticoagulation can be resumed immediately for smaller lesions, and within one week in those with large areas of infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, given the risk of inducing intracerebral hemorrhage with anticoagulation in patients with prosthetic heart valve IE and an embolic event, a more conservative approach seems appropriate for patients with endocarditis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is a compelling need to reinstitute anticoagulant therapy during the first two weeks following the onset of stroke, serial brain imaging with CT or MRI should be performed to exclude hemorrhagic transformation or intraparenchymal hemorrhage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiography, preferably noninvasive contrast angiography with CT, may be necessary to exclude a mycotic aneurysm in selected patients who have evidence of hemorrhage by routine brain imaging studies and who are candidates for definitive neurosurgical or embolization therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. If CT angiography does not show a mycotic aneurysm in such patients, a conventional invasive angiogram is required as the definitive test. If a symptomatic mycotic aneurysm is detected by angiography, resumption of anticoagulation should be postponed until definitive treatment has been achieved. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link\">",
"       \"Overview of infected (mycotic) arterial aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serial neuroimaging and angiography are not indicated for patients without hemorrhagic transformation who do not require anticoagulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Native or bioprosthetic valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for anticoagulation in a patient with either a native valve IE or bioprosthetic valve IE and cerebral embolism are not clear. Anticoagulation is not routinely recommended because there is persuasive evidence of the risk of intracerebral hemorrhage without solid countervailing evidence of benefit.",
"   </p>",
"   <p>",
"    However, clinicians may be reasonably guided to use or withhold anticoagulation according to the following additional considerations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link&amp;anchor=H8#H8\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\", section on 'Bioprosthetic valves'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=see_link&amp;anchor=H2#H2\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'ICH risk with antithrombotic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The perceived risk of additional emboli",
"     </li>",
"     <li>",
"      The presence or absence of a left atrial thrombus",
"     </li>",
"     <li>",
"      The perceived or expected efficacy of the antibiotic treatment",
"     </li>",
"     <li>",
"      The presence of hypertension, atrial fibrillation, or other comorbid features (eg, venous thromboembolism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Concurrent indication for anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of anticoagulation in patients with IE and other concurrent conditions (eg, deep vein thrombosis, surgical repair or replacement of an infected valve) is unresolved. Anticoagulant therapy can reasonably be initiated in individual patients after brain imaging studies have excluded the presence of asymptomatic or subclinical stroke. However, in general, anticoagulation should be discontinued if signs of central nervous system embolism occur. An inferior vena caval filter is an option for selected patients with deep vein thrombosis who are not candidates for anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Heparin versus warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an unresolved and ongoing controversy over whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be used when anticoagulation is warranted for the treatment of patients with IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3,13,14,30,31\">",
"     3,13,14,30,31",
"    </a>",
"    ]. We generally prefer warfarin with an International Normalized Ratio (INR) maintained between 2.5 to 3.0. However, when there is increased concern about the risk of intracerebral bleeding, or for those patients requiring placement of central venous access or other procedures, heparin anticoagulation has the advantage of permitting more rapid reversal of anticoagulation.",
"   </p>",
"   <p>",
"    Care must be taken with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients receiving antibiotics, as these may change the metabolism of this agent. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    induces cytochrome enzymes that accelerate the metabolism of warfarin. Thus, rifampin therapy will markedly increase the daily dose of warfarin required for effective anticoagulation, and the discontinuation of rifampin will necessitate a reduction in the daily dose. For some patients who will be on a prolonged course of antibiotics, conversion of the patient to therapeutic-dose low-molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be an alternative strategy for effective, safe anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H16#H16\">",
"     \"Therapeutic use of warfarin\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/1\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/2\">",
"      Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/3\">",
"      Davenport J, Hart RG. Prosthetic valve endocarditis 1976-1987. Antibiotics, anticoagulation, and stroke. Stroke 1990; 21:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/4\">",
"      Pruitt AA, Rubin RH, Karchmer AW, Duncan GW. Neurologic complications of bacterial endocarditis. Medicine (Baltimore) 1978; 57:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/5\">",
"      Di Salvo G, Habib G, Pergola V, et al. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol 2001; 37:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/6\">",
"      Snygg-Martin U, Gustafsson L, Rosengren L, et al. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis 2008; 47:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/7\">",
"      Rasmussen RV, Snygg-Martin U, Olaison L, et al. Major cerebral events in Staphylococcus aureus infective endocarditis: is anticoagulant therapy safe? Cardiology 2009; 114:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/8\">",
"      Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 2003; 42:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/9\">",
"      Tornos P, Almirante B, Mirabet S, et al. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med 1999; 159:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/10\">",
"      Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/11\">",
"      Dickerman SA, Abrutyn E, Barsic B, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J 2007; 154:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/12\">",
"      Paschalis C, Pugsley W, John R, Harrison MJ. Rate of cerebral embolic events in relation to antibiotic and anticoagulant therapy in patients with bacterial endocarditis. Eur Neurol 1990; 30:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/13\">",
"      Wilson WR, Geraci JE, Danielson GK, et al. Anticoagulant therapy and central nervous system complications in patients with prosthetic valve endocarditis. Circulation 1978; 57:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/14\">",
"      Leport C, Vilde JL, Bricaire F, et al. Fifty cases of late prosthetic valve endocarditis: improvement in prognosis over a 15 year period. Br Heart J 1987; 58:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/15\">",
"      Yeh TJ, Anabtawi IN, Cornett VE, Ellison RG. Influence of rhythm and anticoagulation upon the incidence of embolization associated with Starr-Edwards prostheses. Circulation 1967; 35:I77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/16\">",
"      Carpenter JL, McAllister CK. Anticoagulation in prosthetic valve endocarditis. South Med J 1983; 76:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/17\">",
"      Lieberman A, Hass WK, Pinto R, et al. Intracranial hemorrhage and infarction in anticoagulated patients with prosthetic heart valves. Stroke 1978; 9:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/18\">",
"      Hart RG, Kagan-Hallet K, Joerns SE. Mechanisms of intracranial hemorrhage in infective endocarditis. Stroke 1987; 18:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/19\">",
"      Masuda J, Yutani C, Waki R, et al. Histopathological analysis of the mechanisms of intracranial hemorrhage complicating infective endocarditis. Stroke 1992; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/20\">",
"      Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999; 99:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/21\">",
"      Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 2003; 112:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/22\">",
"      Anavekar NS, Tleyjeh IM, Anavekar NS, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis 2007; 44:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/23\">",
"      Chan KL, Tam J, Dumesnil JG, et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis 2008; 46:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/24\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/25\">",
"      Immediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group. Stroke 1983; 14:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/26\">",
"      Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Cerebral Embolism Study Group. Stroke 1984; 15:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/27\">",
"      Scott WR, New PF, Davis KR, Schnur JA. Computerized axial tomography of intracerebral and intraventricular hemorrhage. Radiology 1974; 112:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/28\">",
"      Salgado AV, Furlan AJ, Keys TF. Mycotic aneurysm, subarachnoid hemorrhage, and indications for cerebral angiography in infective endocarditis. Stroke 1987; 18:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/29\">",
"      Brust JC, Dickinson PC, Hughes JE, Holtzman RN. The diagnosis and treatment of cerebral mycotic aneurysms. Ann Neurol 1990; 27:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/30\">",
"      Delahaye JP, Poncet P, Malquarti V, et al. Cerebrovascular accidents in infective endocarditis: role of anticoagulation. Eur Heart J 1990; 11:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33415/abstract/31\">",
"      Horstkotte D, Piper C, Niehues R, et al. Late prosthetic valve endocarditis. Eur Heart J 1995; 16 Suppl B:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1329 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33415=[""].join("\n");
var outline_f32_40_33415=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT AND DISEASE RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk of embolic stroke in IE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Native valve IE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Prosthetic valve IE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mechanisms of intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use of aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mechanical heart valves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Patients with stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Native or bioprosthetic valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Concurrent indication for anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Heparin versus warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33416="Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma";
var content_f32_40_33416=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33416/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/40/33416/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-Hodgkin lymphoma subtype of marginal zone lymphoma includes three distinct diseases that have been historically classified together because they appear to arise from post-germinal center marginal zone B cells and share a similar immunophenotype: positive for B cell markers CD19, CD20, and CD22, and negative for CD5, CD10, and usually CD23 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three diseases in this category that are recognized in the 2008 WHO classification system of lymphoid neoplasms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic marginal zone B cell lymphoma (&plusmn; villous lymphocytes)",
"     </li>",
"     <li>",
"      Extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) type (MALT-type lymphoma, MALT lymphoma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nodal marginal zone B cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the fact that splenic MZL may have a marginal zone pattern, there is no clinical overlap with extranodal MZL (MALT lymphoma) and nodal MZL; these diseases appear to be completely unrelated. As such, we present them separately.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, pathology, and diagnosis of splenic marginal zone lymphoma will be discussed here. Extranodal marginal zone B cell lymphoma and nodal marginal zone B cell lymphoma are discussed separately, as is the treatment of these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22169?source=see_link\">",
"     \"Treatment of marginal zone (MALT) lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic MZL constitutes &lt;5 percent of all NHLs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/5\">",
"     5",
"    </a>",
"    ], 1 to 2 percent of indolent lymphoid leukemias found on bone marrow examination, and up to 25 percent of low grade B cell neoplasms in splenectomy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. It comprises the majority of chronic B cell leukemias and low-grade splenic lymphomas that do not fit the defining criteria of B cell CLL, lymphoplasmacytic lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10\">",
"     10",
"    </a>",
"    ], mantle cell lymphoma, follicular lymphoma, or hairy cell leukemia.",
"   </p>",
"   <p>",
"    Splenic MZL occurs at a median age of 65; the disease is uncommon before age 50. There is no gender predominance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic MZL is postulated to arise from a post germinal center, memory B cell of splenic type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/3\">",
"     3",
"    </a>",
"    ]. The pathogenesis of disease is unclear. Study of splenic MZL has been hampered historically by heterogeneous diagnostic criteria. More cohesive diagnostic criteria outlined in the 2008 WHO classification of lymphoid neoplasms may help identify a more homogenous group of tumors.",
"   </p>",
"   <p>",
"    As an example, one study used WHO criteria for case identification and performed cDNA microarray analysis and tissue microarray profiling; these tumor samples shared a characteristic gene expression signature consistent with their classification as a single disease. Overexpressed genes included those involved in B cell receptor and tumor necrosis factor (TNF) signaling, and NF-KB activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/11\">",
"     11",
"    </a>",
"    ]. Although the molecular pathways are unclear, these data suggest that current disease definitions are more accurate and will allow more systematic studies of pathogenesis.",
"   </p>",
"   <p>",
"    A subset of cases demonstrates defects in the regulation of normal pathways of marginal zone B cell development. A whole-genome sequencing study that compared samples from eight patients with splenic MZL and normal paired germ line control material identified recurrent somatic mutations in genes involved in the NOTCH, NF-KB, and B cell receptor pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/12\">",
"     12",
"    </a>",
"    ]. Other mutations were seen in TP53 and in genes involved in chromatin remodeling and transcriptional regulation. Directed sequencing of these genes in an expanded population of 117 cases confirmed mutations in genes involved in the NOTCH pathway including NOTCH2 (21 percent), NOTCH1 (5 percent), and SPEN (5 percent). Analysis in a separate cohort of 99 cases of splenic MZL identified NOTCH2 mutations in approximately 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/13\">",
"     13",
"    </a>",
"    ]. NOTCH2 mutations were associated with a poor clinical outcome.",
"   </p>",
"   <p>",
"    Epidemiologic studies have identified an association between splenic MZL and infection with viruses, such as hepatitis C virus and Kaposi&rsquo;s sarcoma-associated herpes virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one study, treatment of the hepatitis C infection induced regression of splenic MZL in some patients, and lymphoma disease activity and hepatitis C viral load were correlated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/14\">",
"     14",
"    </a>",
"    ]. Since marginal zone lymphomas often arise in the setting of a sustained immunologic stimulus (eg, gastric marginal zone lymphoma typically arises in the setting of H. pylori infection), it is possible that hepatitis C antigens provide such a stimulus in cases that are hepatitis C-associated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically present with splenomegaly, lymphocytosis, and cytopenias (most often due to hypersplenism) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10,16-18\">",
"     10,16-18",
"    </a>",
"    ]. Unlike most other NHLs, lymphadenopathy and involvement of extralymphatic organs is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/19\">",
"     19",
"    </a>",
"    ]. Systemic markers of disease such as B symptoms or an elevated lactate dehydrogenase (LDH) are rare and should lead to a more detailed investigation of possible transformation to a more aggressive lymphoma.",
"   </p>",
"   <p>",
"    Peripheral blood, focal bone marrow involvement, and liver infiltration are common; 90 percent or more of cases have stage IV disease at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10,20\">",
"     10,20",
"    </a>",
"    ]. Rare patients will present with lymphocytosis as their sole marker of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, approximately one-third of patients have a small amount of circulating monoclonal protein, often IgM. In those with hepatitis C infection, mixed cryoglobulinemia and an associated small vessel vasculitis may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acquired C1 esterase deficiency can be seen with lymphoproliferative disorders such as splenic marginal zone lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a patient with suspected splenic MZL should include a full blood count with review of the peripheral smear, histologic review of the bone marrow aspirate and biopsy, immunophenotypic analysis of the tumor cells, and measurement of serum immunoglobulins. Other studies that may be of use in determining the diagnosis include a histologic review of splenic tissue and genetic mutation analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic MZL (&plusmn; villous lymphocytes) is a neoplasm of small B lymphocytes that surround and replace splenic white pulp germinal centers, merging with an outer marginal zone of larger cells with pale cytoplasm, and admixed with large transformed blasts. Both small and large cells infiltrate red pulp, often with villous lymphocytes circulating in the peripheral blood (",
"    <a class=\"graphic graphic_picture graphicRef59065 \" href=\"mobipreview.htm?35/23/36209\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the peripheral blood is common in splenic MZL. While there is morphologic heterogeneity, a typical tumor cell resembles a lymphocyte with a round nucleus, condensed chromatin, and abundant basophilic cytoplasm with small surface \"villous\" projections (",
"    <a class=\"graphic graphic_picture graphicRef59065 \" href=\"mobipreview.htm?35/23/36209\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10,18,25\">",
"     10,18,25",
"    </a>",
"    ]. These projections are often unevenly distributed around the circumference of the cell. Of importance, exposure of these cells to anticoagulants used in specimen storage can result in loss of these projections. Examination of a slide made from freshly drawn blood may be required to identify projections in suspected cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18\">",
"     18",
"    </a>",
"    ]. Less commonly, tumor cells may appear plasmacytoid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Spleen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic examination of the spleen demonstrates involvement of both the white and red pulp in practically all cases of splenic MZL. In the white pulp, the neoplastic cells occupy both the mantle and marginal zones, usually with a central residual germinal center, which may be either atrophic or hyperplastic (",
"    <a class=\"graphic graphic_picture graphicRef72336 \" href=\"mobipreview.htm?39/24/40324\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/6,7,26\">",
"     6,7,26",
"    </a>",
"    ]. Both the mantle and marginal zones are expanded. The cells in the mantle zone are small, with slight nuclear irregularity and scant cytoplasm, while those in the marginal zone have more dispersed chromatin and abundant, pale cytoplasm, resembling marginal zone cells, and are admixed with variable numbers of larger activated cells resembling immunoblasts. In some tumors there is also a degree of plasmacytic differentiation.",
"   </p>",
"   <p>",
"    The red pulp demonstrates both a diffuse and micronodular pattern of involvement with sinus infiltration. Epithelioid histiocytes may be present singly or in clusters, and, particularly in the bone marrow, may be so conspicuous as to raise the differential possibility of an infectious process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic hilar lymph nodes are often involved; the neoplastic cells form vague nodules, often without a central germinal center; a marginal zone pattern may or may not be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/27\">",
"     27",
"    </a>",
"    ]. Sinuses are often preserved and dilated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bone marrow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow involvement, if present, is often mild and can be subtle. The marrow usually contains discrete lymphoid aggregates, which may also have a marginal zone pattern, with or without diffuse intrasinusoidal lymphoid infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. The nodular pattern of involvement can be helpful in distinguishing splenic MZL from hairy cell leukemia, which always involves the marrow in a diffuse interstitial pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells express surface immunoglobulin (eg, IgM+, IgD+), B cell antigens (CD19, CD20, CD22) and BCL-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/6,28\">",
"     6,28",
"    </a>",
"    ]. They typically are CD5-, CD10-, CD43-, CD23-, and CD25-. Expression of CD21 and CD35 is variable. The majority of splenic MZL expresses many of the adhesion molecules, including LFA-1, CD44, CD49d, CD29, ICAM-1, but lack L-selectin. The cells are cyclin D1 negative by immunoperoxidase staining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of CD5 serves to distinguish SMZL from B cell chronic lymphocytic",
"      <span class=\"nowrap\">",
"       leukemia/small",
"      </span>",
"      lymphocytic lymphoma and mantle cell lymphoma.",
"     </li>",
"     <li>",
"      Lack of CD103 and CD25 are useful in distinguishing SMZL from hairy cell leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 80 percent of patients with splenic MZL will have an abnormal karyotype, often with complex chromosomal changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ]. No characteristic genetic abnormalities have been identified.",
"   </p>",
"   <p>",
"    Analysis of the immunoglobulin variable region genes shows somatic mutations in approximately half of cases, consistent with a post-germinal center stage of B cell development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/11,32,33\">",
"     11,32,33",
"    </a>",
"    ]. Ongoing mutation of V region genes, similar to germinal center cells, has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/34\">",
"     34",
"    </a>",
"    ]. Earlier reports that the t(11;14)(q13;q32) rearrangement, and cyclin D1 overexpression were common are now thought to have stemmed from inclusion of cases of leukemic mantle cell lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. BCL-2 is germline. Trisomy 3, found in nodal and extranodal marginal zone lymphoma, is detected in up to 39 percent of cases of splenic MZL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], although, unlike in these other disorders, the t(11;18) is lacking in splenic MZL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of splenic MZL is made based on evaluation of the lymphocyte morphology, immunophenotype, cytogenetic analysis, bone marrow histology, and spleen histology, when available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18\">",
"     18",
"    </a>",
"    ]. The diagnosis of splenic MZL can most readily be made according to one of the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The splenic histology and immunophenotypic pattern are consistent with splenic MZL, as described above.",
"     </li>",
"     <li>",
"      If splenic tissue is not available for histologic review, the diagnosis of splenic MZL can be made in a patient with clinical splenomegaly and typical morphologic and immunophenotypic findings on blood smear and bone marrow biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with splenic MZL present with splenomegaly and lymphocytosis. There are numerous infectious (eg, infectious mononucleosis, pertussis, toxoplasmosis) and neoplastic conditions other than splenic MZL that can present in this way. Those that are most common are other low-grade B cell proliferations involving the spleen. While some morphologic characteristics are helpful, the most reliable means of distinguishing these tumors is immunophenotyping. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Follicular lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;While both splenic MZL and follicular lymphoma have a nodular growth pattern, the nodules of splenic MZL tend to be more uniform in size. Follicular lymphoma cells are most often found in the white pulp and consist of a mixture of centrocytes (small cleaved cells) and centroblasts. Unlike splenic MZL, follicular lymphoma cells express CD10 and BCL-6. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=see_link\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mantle cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much like splenic MZL, mantle cell lymphoma (MCL) can infiltrate both the red and white pulp of the spleen. In general, these two can be distinguished based upon histology and immunophenotype. On histology, MCL tumor cells are monomorphous small to medium-sized B lymphocytes while splenic MZL often contains a population of large immunoblast-like cells, cells with abundant pale cytoplasm (monocytoid B cell-like cells),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cells exhibiting plasmacytic differentiation. In addition, the vast majority of MCL tumor cells overexpress cyclin D1 while splenic MZL cells do not. Lack of CD5 can also serve to distinguish splenic MZL from MCL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic lymphocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most cases of splenic involvement in CLL demonstrate diffuse infiltration of both the red and white pulp with effacement of the follicles, there are some cases that may appear micronodular and involve the marginal zones of the white pulp. In addition, both CLL and splenic MZL can express CD23, CD43, CD5, and IgD, although expression of these is much more typical of CLL. In difficult cases, evaluation of the hilar lymph nodes, peripheral blood, and bone marrow must be used in concert to determine the most likely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=see_link\">",
"     \"Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hairy cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hairy cell leukemia (HCL) only involves the red pulp of the spleen, where it often produces dilated sinusoids filled with blood (blood lakes), and as mentioned above never involves the marrow in a nodular pattern. Thus splenic white pulp involvement or nodular bone marrow involvement excludes the diagnosis of HCL. Hairy cell leukemia and splenic MZL are also easily differentiated from each other by immunophenotype. Unlike HCL, splenic MZL tumors do not express CD103 or CD25. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=see_link\">",
"     \"Clinical features and diagnosis of hairy cell leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphoplasmacytic lymphoma can involve the spleen and bone marrow and may be difficult to distinguish from splenic MZL. Both tumors can have plasma cell differentiation (although it is usually much more prominent in lymphoplasmacytic lymphoma) and similar patterns of spleen and bone marrow involvement. The presence of prominent \"monocytoid\" B cells in the splenic white pulp marginal zones is typical of splenic MZL and can be helpful in making this distinction, as can the presence of \"villous\" lymphocytes in the peripheral blood. Finally, although splenic MZL may be associated with a small monoclonal immunoglobulin spike, large spikes are not seen and, if present, strongly support the diagnosis of lymphoplasmacytic lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     MALT lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of marginal zone lymphoma originating at mucosal sites (so-called MALT lymphoma) can disseminate to nodal sites, spleen, and bone marrow. In such cases it may be unclear exactly where the disease originated. The only definitive clue is detection of the t(11;18), t(14;18) (in this case involving the MALT1 gene on chromosome 18), the t(1;14), or the t(3;14), all of which may be seen in MALT lymphomas but not splenic MZL. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2089207\">",
"    <span class=\"h2\">",
"     Splenic B cell lymphoma/leukemia, unclassifiable",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a small number of splenic B cell neoplasms comprised predominantly of small cells that do not fit any of the typical diagnostic categories. One provisional entity described in the 2008 WHO classification carries the descriptive name &ldquo;splenic diffuse red pulp small B cell lymphoma&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/3\">",
"     3",
"    </a>",
"    ]. As the name implies, this tumor shows diffuse involvement of red pulp cords and sinusoids, and does not involve the white pulp follicles or marginal zones. Marrow involvement most commonly takes the form of sinusoidal infiltrates; while nodular interstitial infiltrates can also be seen in the marrow, marginal zone growth about reactive-appearing follicles, often seen in splenic MZL, is absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of splenic MZL is generally extremely indolent, with a median overall survival in excess of 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, some patients appear to have a more aggressive course with a median survival of 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/20\">",
"     20",
"    </a>",
"    ]. Two main prognostic scores have been developed for patients with splenic MZL: the Splenic Marginal Zone Lymphoma Study Group (SMZLSG) prognostic score and the Intergruppo Italiano Linfomi (ILL) prognostic score. Of these, the SMZLSG prognostic score appears to be more cumbersome, but better able to discriminate between low and intermediate risk groups.",
"   </p>",
"   <p>",
"    The ILL prognostic score was developed based upon data from 309 patients with splenic MZL diagnosed between 1989 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/43\">",
"     43",
"    </a>",
"    ]. The overall cause-specific five-year survival rate was 76 percent, with the following three factors being predictive of shorter survival on multivariate analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin &lt;12",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase (LDH) level greater than normal",
"     </li>",
"     <li>",
"      Serum albumin level &lt;3.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient who had zero, one, or two to three of these adverse risk factors had five-year cause-specific survival rates of 88, 73, and 50 percent, respectively. When applied to an expanded cohort of 450 patients with splenic MZL, corresponding five-year survival rates were 95, 90, and 79 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SMZLSG prognostic score was subsequently developed using data from 366 patients with splenic MZL and validated in an independent cohort of 227 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/44\">",
"     44",
"    </a>",
"    ]. This score uses information on the hemoglobin",
"    <span class=\"nowrap\">",
"     (g/L),",
"    </span>",
"    platelet count",
"    <span class=\"nowrap\">",
"     (10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    LDH (LDH score 1 point if high, 0 points if normal), and the presence of extrahilar lymphadenopathy (LAD score, 1 point if present, 0 points if absent) in the following equation: &nbsp;",
"   </p>",
"   <p>",
"    Prognostic index (PI) = (0.02 x hemoglobin) + (0.006 x platelet count) &ndash; (1 x LDH score) &ndash; (1 x LAD score) &nbsp;",
"   </p>",
"   <p>",
"    Using this information, patients were separated into three prognostic groups with the following estimated lymphoma-specific survival at five years:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low risk (PI&ge;2.6) &ndash; 94 and 96 percent in derivation and validation cohorts, respectively",
"     </li>",
"     <li>",
"      Intermediate risk (PI&ge;0.9 and &lt;2.6) &ndash; 78 and 88 percent in derivation and validation cohorts, respectively",
"     </li>",
"     <li>",
"      High risk (PI&lt;0.9) &ndash; 69 and 44 percent in derivation and validation cohorts, respectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SMZLSG prognostic score was compared with the ILL prognostic score using a cohort of 450 patients with splenic MZL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/44\">",
"     44",
"    </a>",
"    ]. While both scores were able to distinguish the high risk group from the other two, the SMZLSG was better able to separate the low and intermediate risk groups.",
"   </p>",
"   <p>",
"    Other prognostic factors have been investigated, including abnormalities in p53 (deletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    expression) and expression of NF-kappa B signature genes, but such tests are not currently clinically applicable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/11,20,45,46\">",
"     11,20,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to other indolent lymphomas, MZL has the potential to transform into a high-grade lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10,38,47\">",
"     10,38,47",
"    </a>",
"    ]. The diagnosis and treatment of histologic transformation to an aggressive NHL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic marginal zone lymphoma (MZL) has been historically classified with extranodal (MALT) and nodal marginal zone lymphoma as they all appear to arise from post-germinal center marginal zone B cells and share a similar immunophenotype. However, these lymphoma subtypes are clinically distinct. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenic MZL constitutes &lt;5 percent of all non-Hodgkin lymphomas (NHLs). Almost all patients present after the age of 50 years. The median age at diagnosis is 65 years. There is no gender predominance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of splenic MZL is unknown. A subset of cases demonstrates defects in the regulation of normal pathways of marginal zone B cell development (eg, NOTCH, NF-KB, and B cell receptor pathways). Marginal zone lymphomas often arise in the setting of a sustained immunologic stimulus. Epidemiologic studies have identified an association between splenic MZL and infection with hepatitis C virus; thus, it is possible that hepatitis C antigens provide such a stimulus in cases that are hepatitis C-associated. Such cases may also be associated with mixed cryoglobulinemia. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with splenomegaly, lymphocytosis, and cytopenias (most often due to hypersplenism). Unlike most other NHLs, lymphadenopathy, involvement of extralymphatic organs, systemic B symptoms, and elevated lactate dehydrogenase levels are uncommon. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Involvement of the peripheral blood is common in splenic MZL. While there is morphologic heterogeneity, a typical tumor cell resembles a lymphocyte with a round nucleus, condensed chromatin, and abundant basophilic cytoplasm with small surface \"villous\" projections (",
"      <a class=\"graphic graphic_picture graphicRef59065 \" href=\"mobipreview.htm?35/23/36209\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Peripheral blood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of splenic MZL is made based on evaluation of the lymphocyte morphology, immunophenotype, cytogenetic analysis, bone marrow histology, and spleen histology, when available. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pathologic examination of the spleen demonstrates involvement of both the white and red pulp in practically all cases. In the white pulp, the neoplastic cells occupy both the mantle and marginal zones, usually with a central residual germinal center, which may be either atrophic or hyperplastic (",
"      <a class=\"graphic graphic_picture graphicRef72336 \" href=\"mobipreview.htm?39/24/40324\">",
"       picture 2",
"      </a>",
"      ). The red pulp demonstrates both a diffuse and micronodular pattern of involvement with sinus infiltration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Spleen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenic hilar lymph nodes are often involved and can be key to making the diagnosis in complicated cases. Bone marrow involvement, if present, is often mild and can be subtle. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lymph nodes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Bone marrow'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tumor cells express surface immunoglobulin (eg, IgM+, IgD+), B cell antigens (CD19, CD20, CD22) and bcl-2. They typically are CD5-, CD10-, CD43-, CD23-, and CD25-. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Immunophenotype'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 80 percent of patients with splenic MZL will have an abnormal karyotype, often with complex chromosomal changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18\">",
"       18",
"      </a>",
"      ]. No characteristic genetic abnormalities have been identified. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Genetic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with splenic MZL present with splenomegaly and lymphocytosis. There a numerous infectious (eg, infectious mononucleosis, pertussis, toxoplasmosis) and neoplastic conditions other than splenic MZL that can present in this way. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The course of splenic MZL is usually extremely indolent, with a median overall survival in excess of 10 years. However, some patients appear to have a more aggressive course. Levels of hemoglobin, lactate dehydrogenase, and albumin have been proposed as potential predictors of survival. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similar to other indolent lymphomas, splenic MZL has the potential to transform into a high-grade lymphoma. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5433?source=see_link\">",
"       \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/4\">",
"      Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 1999; 36:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/5\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/6\">",
"      Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994; 84:3828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/7\">",
"      Mollejo M, Men&aacute;rguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am J Surg Pathol 1995; 19:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/8\">",
"      Pittaluga S, Verhoef G, Criel A, et al. \"Small\" B-cell non-Hodgkin's lymphomas with splenomegaly at presentation are either mantle cell lymphoma or marginal zone cell lymphoma. A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis. Am J Surg Pathol 1996; 20:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/9\">",
"      Arber DA, Rappaport H, Weiss LM. Non-Hodgkin's lymphoproliferative disorders involving the spleen. Mod Pathol 1997; 10:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/10\">",
"      Audouin J, Le Tourneau A, Molina T, et al. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003; 122:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/11\">",
"      Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/12\">",
"      Rossi D, Trifonov V, Fangazio M, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012; 209:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/13\">",
"      Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012; 209:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/14\">",
"      Hermine O, Lefr&egrave;re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/15\">",
"      Benavente Y, Mbisa G, Labo N, et al. Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study. Br J Cancer 2011; 105:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/16\">",
"      Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/17\">",
"      Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood 2003; 101:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/18\">",
"      Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008; 22:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/19\">",
"      Melo JV, Hegde U, Parreira A, et al. Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol 1987; 40:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/20\">",
"      Chac&oacute;n JI, Mollejo M, Mu&ntilde;oz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002; 100:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/21\">",
"      Zignego AL, Giannini C, Monti M, Gragnani L. Hepatitis C virus lymphotropism: lessons from a decade of studies. Dig Liver Dis 2007; 39 Suppl 1:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/22\">",
"      Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976; 48:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/23\">",
"      Bain BJ, Catovsky D, Ewan PW. Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B-lymphocytes. Cancer 1993; 72:3318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/24\">",
"      Phanish MK, Owen A, Parry DH. Spontaneous regression of acquired C1 esterase inhibitor deficiency associated with splenic marginal zone lymphoma presenting with recurrent angio-oedema. J Clin Pathol 2002; 55:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/25\">",
"      Delsol G, Diebold J, Isaacson PG, et al. Pathology of the spleen: report on the workshop of the VIIIth meeting of the European Association for Haematopathology, Paris 1996. Histopathology 1998; 32:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/26\">",
"      Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol 1992; 16:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/27\">",
"      Mollejo M, Lloret E, Men&aacute;rguez J, et al. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am J Surg Pathol 1997; 21:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/28\">",
"      Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/29\">",
"      Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol 1998; 11:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/30\">",
"      Rinaldi A, Forconi F, Arcaini L, et al. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. Br J Haematol 2010; 151:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/31\">",
"      Rinaldi A, Mian M, Chigrinova E, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011; 117:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/32\">",
"      Zhu D, Oscier DG, Stevenson FK. Splenic lymphoma with villous lymphocytes involves B cells with extensively mutated Ig heavy chain variable region genes. Blood 1995; 85:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/33\">",
"      Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/34\">",
"      Dunn-Walters DK, Boursier L, Spencer J, Isaacson PG. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol 1998; 29:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/35\">",
"      Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol 1993; 85:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/36\">",
"      Jadayel D, Matutes E, Dyer MJ, et al. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene. Blood 1994; 83:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/37\">",
"      Gruszka-Westwood AM, Matutes E, Coignet LJ, et al. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol 1999; 104:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/38\">",
"      Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/39\">",
"      Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 1995; 85:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/40\">",
"      Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol 1996; 9:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/41\">",
"      Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/42\">",
"      Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013; 119:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/43\">",
"      Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107:4643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/44\">",
"      Montalb&aacute;n C, Abraira V, Arcaini L, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2012; 159:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/45\">",
"      Gruszka-Westwood AM, Hamoudi RA, Matutes E, et al. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001; 97:3552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/46\">",
"      Salido M, Bar&oacute; C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010; 116:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33416/abstract/47\">",
"      Dungarwalla M, Appiah-Cubi S, Kulkarni S, et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008; 143:71.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4731 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33416=[""].join("\n");
var outline_f32_40_33416=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Spleen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MALT lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2089207\">",
"      Splenic B cell lymphoma/leukemia, unclassifiable",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4731|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/23/36209\" title=\"picture 1\">",
"      Villous lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/24/40324\" title=\"picture 2\">",
"      Splenic marginal zone NHL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/22/20841?source=related_link\">",
"      Clinical features and diagnosis of hairy cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38872?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/29/30169?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/38/35431?source=related_link\">",
"      Pathologic features, diagnosis, and differential diagnosis of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22169?source=related_link\">",
"      Treatment of marginal zone (MALT) lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33417="What is goal blood pressure in the treatment of hypertension?";
var content_f32_40_33417=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What is goal blood pressure in the treatment of hypertension?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/40/33417/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/40/33417/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic pressure generally rises with increasing age, while diastolic pressure reaches its peak in the fifth decade and subsequently falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/1\">",
"     1",
"    </a>",
"    ]. These features are a reflection of the slow decrease in the compliance of the large capacitance vessels.",
"   </p>",
"   <p>",
"    The net effect is that the risk from hypertension varies in part with age:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among untreated patients less than 65 years old, there is a progressive increase in the risk of stroke and coronary disease with increasing blood pressure (BP). The risk is greater for each increment in systolic pressure than for the equivalent increase in diastolic pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For individuals over age 65, the risk continues to increase with the rising systolic pressure. However, a reversal occurs with the diastolic pressure: the lower the diastolic pressure at a given systolic pressure, the greater the risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/3\">",
"       3",
"      </a>",
"      ]. Thus, an increased pulse pressure is associated with an increased risk of an adverse event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative prognostic importance of the different blood pressure components in individuals of different ages was perhaps best studied among participants in the Second National Health and Nutrition Examination Survey (NHANES II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/4\">",
"     4",
"    </a>",
"    ]. In this cohort study of 7830 participants between the ages of 30 to 74 years who were initially free of cardiovascular disease, the baseline blood pressure was correlated with all-cause and cardiovascular mortality over a 15 year follow-up. Over this period, 1588 patients died, with cardiovascular disease being responsible in 582 (37 percent).",
"   </p>",
"   <p>",
"    Unlike previous studies, the analysis was based upon a generalized additive risk model that utilized the correlation between systolic and diastolic blood pressures to estimate the risk for different baseline blood pressure combinations. As a result, the risk associated with a blood pressure of",
"    <span class=\"nowrap\">",
"     150/100",
"    </span>",
"    mmHg could be ascertained, whereas other studies permitted determination of the risk of a systolic pressure of 150 mmHg or a diastolic pressure of 100 mmHg, but not the combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/5\">",
"     5",
"    </a>",
"    ]. In the latter studies, the risk attributed to a diastolic pressure of 100 mmHg was a composite of the range of systolic pressures associated with this diastolic pressure.",
"   </p>",
"   <p>",
"    The following results were obtained concerning mortality beyond the first two years of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among participants less than 65 years of age, increases in the systolic blood pressure were linearly related to increases in cardiovascular and all-cause mortality at",
"      <strong>",
"       all",
"      </strong>",
"      diastolic blood pressure levels. By comparison, the correlation between diastolic blood pressure and mortality in this age group was \"hockey stick-shaped\". This shape corresponds to a flat region of risk with diastolic values below 80 mmHg, with a marked increase in risk occurring with values above this level.",
"     </li>",
"     <li>",
"      Among those greater than 65 years of age, increases in the systolic pressure were also linearly related to increased mortality at all diastolic pressures. However, the risk with the diastolic pressure was J-shaped; thus, for a fixed systolic pressure, increasing diastolic pressure that was below approximately 80 to 90 mmHg was associated with a decreased risk of mortality, while increasing diastolic pressure above 80 to 90 mmHg was associated with an enhanced risk.",
"     </li>",
"     <li>",
"      Increased pulse pressure was associated with marked variations in risk of mortality, depending upon age, and the exact systolic and diastolic pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increasing number of trials have provided evidence that antihypertensive therapy that results in adequate blood pressure control provides some degree of cardiovascular protection. However, the optimal level of control is unclear and may vary with certain patient populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/6\">",
"     6",
"    </a>",
"    ]. In general, the benefits of increasingly intensive therapy must be weighed against the potentially increased incidence of serious side effects associated with such a regimen.",
"   </p>",
"   <p>",
"    The rationale for specific goal blood pressure levels in the general hypertensive population and the possible risks of excessive blood pressure lowering will be reviewed here. The indications for antihypertensive therapy in mild hypertension, the choice of antihypertensive drugs for the initial treatment of hypertension, and goal blood pressure in patients with atherosclerotic cardiovascular disease, diabetes mellitus, and chronic kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYSTOLIC AND DIASTOLIC HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systolic and diastolic hypertension in the general population are defined as a blood pressure",
"    <span class=\"nowrap\">",
"     &ge;140/&ge;90",
"    </span>",
"    mmHg measured on at least three separate occasions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypertension: Who should be treated?\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Benefits of blood pressure reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials of antihypertensive therapy demonstrated significant cardiovascular benefit in patients with systolic and diastolic hypertension that was most pronounced in severe and moderate disease. Although the number of patients was small in the severe and moderate hypertension trials, the magnitude of benefit was extremely high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Severe hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best data on the treatment of severe diastolic hypertension come from a trial of 143 men with diastolic pressures of 115 to 129 mmHg (average clinic blood pressure",
"    <span class=\"nowrap\">",
"     186/121",
"    </span>",
"    mmHg) who were randomly assigned to antihypertensive therapy or placebo, the incidence of cardiovascular events was 3 percent at 21 months in the treated group versus 39 percent at 16 months in the placebo group (p&lt;0.001) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/7\">",
"     7",
"    </a>",
"    ]. The shorter follow-up in the placebo group was due to the high number of terminating events. The average blood pressure during the trial was significantly lower in the treated group",
"    <span class=\"nowrap\">",
"     (143/91",
"    </span>",
"    mmHg versus no significant change in the placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Moderate hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of treating moderate diastolic hypertension was demonstrated in a trial of 210 men with diastolic pressures of 105 to 114 mmHg who were randomly assigned to antihypertensive drugs or placebo, the incidence of cardiovascular events at five years was significantly lower in the treated group (8 versus 32 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mild hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absolute benefit of blood pressure lowering is much lower in patients with mild hypertension (diastolic pressures of 90 to 104 mmHg). A summary of the results from 17 controlled trials of mild to moderate diastolic hypertension (almost all also had systolic hypertension) in adults under age 65 found that active treatment with antihypertensive medications (which produced a mean reduction in diastolic pressure of 5 to 6 mmHg) led to a statistically significant 16 percent reduction in the number of coronary events and a 40 percent reduction in stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/9\">",
"     9",
"    </a>",
"    ]. In the aggregate, antihypertensive therapy for four to five years prevented a coronary event in 0.7 percent of patients and a cerebrovascular event in 1.3 percent for a total absolute benefit of approximately",
"    <strong>",
"     2 percent",
"    </strong>",
"    ; this included an absolute reduction in cardiovascular mortality of 0.8 percent (",
"    <a class=\"graphic graphic_figure graphicRef52231 \" href=\"mobipreview.htm?43/29/44509\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are",
"    <strong>",
"     no",
"    </strong>",
"    randomized trials that have evaluated the efficacy of treating mild hypertension in patients with baseline systolic pressures of 140 to 149 mmHg. The three largest randomized trials that have been performed &mdash; the Medical Research Council (MRC) trial, the Hypertension Detection and Follow-up Program (HDFP), and the FEVER trial &mdash; included patients with mean baseline systolic pressures of 150 to 160 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. All showed significant benefit from antihypertensive therapy, which lowered the mean blood pressure to less than 140 mmHg systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less than 90 mmHg diastolic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRC trial &ndash; In the MRC trial, 17,354 patients with a baseline diastolic pressure 90 to 109 mmHg were randomly assigned to bendrofluazide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/10\">",
"       10",
"      </a>",
"      ]. The mean baseline blood pressure was approximately",
"      <span class=\"nowrap\">",
"       161/98",
"      </span>",
"      mmHg; the mean attained blood pressure was approximately",
"      <span class=\"nowrap\">",
"       137/86",
"      </span>",
"      in the two treated groups and",
"      <span class=\"nowrap\">",
"       150/92",
"      </span>",
"      in the placebo group. The treated groups had significantly lower rates of all cardiovascular events (6.7 versus 8.2 per 1000 patient years) and of stroke but not of coronary events or mortality.",
"     </li>",
"     <li>",
"      HDFP trial &ndash; In stratum I of the HDFP trial, 7825 patients with mild hypertension (diastolic pressure 90 to 104 mmHg) were randomly assigned to intensive therapy in special clinics (stepped care) or to usual source of care therapy in the community [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/11\">",
"       11",
"      </a>",
"      ]. The main end point was total mortality at five years, which was significantly lower with stepped care (5.9 versus 7.4 percent, absolute benefit 1.5 percent, 95% CI 0.4-2.6 percent). The magnitude of benefit was similar but not quite significant for the almost 3000 patients with an entry diastolic pressure of 90 to 94 mmHg (absolute benefit 1.6 percent, 95% CI -0.2 to +3.4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/12\">",
"       12",
"      </a>",
"      ]. The average attained diastolic pressure was 85 and 90 mmHg in the stepped care; systolic pressures were not given.",
"     </li>",
"     <li>",
"      FEVER trial &ndash; The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"       Felodipine",
"      </a>",
"      Event Reduction (FEVER) trial included 9800 patients with previously treated hypertension who were switched from previous antihypertensive therapy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      at a dose of 12.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/13\">",
"       13",
"      </a>",
"      ]. At six weeks after switching, the patients were randomly assigned to felodipine or placebo; the baseline blood pressure was",
"      <span class=\"nowrap\">",
"       154/91",
"      </span>",
"      mmHg. Add-on therapy had to be given to 34 and 42 percent of patients, respectively. At a mean follow-up of 40 months, the average blood pressure was lower in the felodipine group",
"      <span class=\"nowrap\">",
"       (137/83",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       143/85",
"      </span>",
"      mmHg with placebo). The primary endpoint of fatal and nonfatal stroke occurred in significantly fewer patients in the felodipine group (3.7 versus 5.2 percent); all-cause mortality was also reduced (2.3 versus 3.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Blood pressure goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general hypertensive population of adults &lt;80 years of age (ie, not including patients at increased risk), we agree with major societies that recommend a goal blood pressure of",
"    <span class=\"nowrap\">",
"     &lt;140/&lt;90",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. However, supportive data for such a goal in patients with grade or stage 1 hypertension (systolic 140-159 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic 90-99 mmHg) are limited. Most trials, except for stratum I in HDFP, included patients whose blood pressure at baseline was higher than these values. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypertension: Who should be treated?\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the aggregate, the above findings from the MRC, HDFP stratum I, and FEVER trials support the recommended goal blood pressure of",
"    <span class=\"nowrap\">",
"     &lt;140/&lt;90",
"    </span>",
"    mmHg in the general hypertensive population. The goal blood pressure may be lower in patients at increased cardiovascular risk due to atherosclerotic cardiovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes mellitus or in patients with proteinuric chronic kidney disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The related issues of whom to treat with antihypertensive therapy, and goal blood pressure in older adult patients with isolated systolic hypertension, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H6#H6\">",
"     \"Hypertension: Who should be treated?\", section on 'Systolic and diastolic hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13441432\">",
"    <span class=\"h3\">",
"     Goal blood pressure versus achieved blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to keep in mind that there is a meaningful difference between goal blood pressure and achieved blood pressure. Many trials have demonstrated that lower",
"    <strong>",
"     achieved",
"    </strong>",
"    blood pressure is associated with superior outcomes, while comparatively few trials have directly evaluated two different",
"    <strong>",
"     goal",
"    </strong>",
"    (ie, target) blood pressures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     J-shaped diastolic curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence related to the possible risk of excessive reduction in the",
"    <strong>",
"     diastolic",
"    </strong>",
"    blood pressure. Rather than demonstrating a progressive benefit at lower pressures, many trials revealed a J-shaped curve in which the risk of cardiac events declines as the diastolic pressure falls from above 100 mmHg to 85 mmHg, but then rises back up at pressures below 80 to 85 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. By comparison, there is little evidence suggesting a J-curve for the",
"    <strong>",
"     systolic",
"    </strong>",
"    blood pressure, other than perhaps isolated systolic hypertension (see below).",
"   </p>",
"   <p>",
"    The following sections will review some of the evidence suggesting that a J-shaped curve does (positive studies) or does not exist (negative studies) for the treatment of diastolic hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Positive studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several long-term reports in patients with diastolic hypertension have evaluated the incidence of cardiovascular complications according to the mean in-study diastolic BP. As mentioned, an enhanced cardiovascular risk of cardiac events has been observed in some studies with diastolic pressures below 80 to 85 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/4,6,18-22\">",
"     4,6,18-22",
"    </a>",
"    ]. This was observed, for example, among individuals greater than 65 years of age who were participants in the NHANES II survey cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/4\">",
"     4",
"    </a>",
"    ]. For a fixed systolic pressure, decreased diastolic pressures below approximately 80 to 90 mmHg were associated with increasing mortality.",
"   </p>",
"   <p>",
"    It is possible that patients with coronary disease do worse at these lower pressures because much of coronary perfusion occurs during diastole; alternatively, low diastolic blood pressures may be a reflection of underlying severe vascular disease, or other chronic illness. Observations from the Framingham study are compatible with the potential importance of underlying coronary disease; a J-shaped curve for coronary deaths was noted for patients who had a myocardial infarction but not for those who did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/19\">",
"     19",
"    </a>",
"    ]. Similarly, in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/37/21079?source=see_link\">",
"     Irbesartan",
"    </a>",
"    Diabetic Nephropathy Trial, there was an increased risk for myocardial infarction, but a lower risk of stroke, with achieved diastolic blood pressures below 85 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/20\">",
"     20",
"    </a>",
"    ], as well as in people with vascular disease in the ONTARGET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/23\">",
"     23",
"    </a>",
"    ] and INVEST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/24\">",
"     24",
"    </a>",
"    ] trials.",
"   </p>",
"   <p>",
"    A secondary analysis of the INVEST trial of over 22,000 patients demonstrated a strong J-shaped relationship between diastolic blood pressure and adverse outcomes (death, nonfatal myocardial infarction or nonfatal stroke) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/21\">",
"     21",
"    </a>",
"    ]. In this study, however, more patients with a mean follow-up diastolic blood pressure less than 70 mmHg had a history of myocardial infarction and heart failure than those with higher diastolic pressures (&gt;40 versus &lt;30 percent, and 10 versus 5 percent, respectively). The J-shaped relationship was markedly attenuated in multivariate analyses adjusted for myocardial infarction, heart failure, and risk factors for cardiovascular disease, suggesting that the J-shaped relationship is partly related to underlying coronary artery disease. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Negative studies'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=see_link&amp;anchor=H13#H13\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'INVEST trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two important factors must be considered from these observations. First, the increase in risk has been noted only at relatively low diastolic pressures,",
"    <strong>",
"     below 70 to 75 mmHg",
"    </strong>",
"    . Second, as will be described in the next section, randomized trials with placebo control have shown a similar J-curve in both treated and placebo groups and for noncardiovascular as well as cardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef73430 \" href=\"mobipreview.htm?18/38/19055\">",
"     figure 2",
"    </a>",
"    ), suggesting that patients with lower diastolic pressures are at higher risk independent of antihypertensive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Negative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of studies that raise serious questions about the importance of the J-curve relating to diastolic blood pressure reduction with antihypertensive medications at usual levels of BP control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/25,27-31\">",
"     25,27-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the first two years of follow-up of over 5000 subjects with a history of a myocardial infarction, there was no detectable association between systolic BP and coronary mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/27\">",
"       27",
"      </a>",
"      ]. Over the ensuing 14 years, however, linear associations were noted between the risk of coronary death and both systolic and diastolic pressure; patients with lower pressures were at lower risk.",
"     </li>",
"     <li>",
"      The Modification of Diet in Renal Disease study suggested that more aggressive BP lowering (systolic pressure below 130 mmHg) slows the rate of progression of chronic renal disease in patients excreting more than 1 to 2 g of protein per day (",
"      <a class=\"graphic graphic_figure graphicRef78190 \" href=\"mobipreview.htm?16/53/17245\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/28\">",
"       28",
"      </a>",
"      ]. An incidental observation was a direct relation between the systolic and diastolic pressures and hospitalization for a first cardiovascular or cerebrovascular event. From the first (88 to 119 mmHg) to the fourth (&gt;138 mmHg) quartiles of systolic pressure, the likelihood of such an event increased progressively from 0.4 to 2.2 to 2.9 to 5.8 percent per patient year of follow-up. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a prospective evaluation of over 6000 patients for nine years, a J-curve did not appear except in patients with mild to moderate hypertension whose diastolic pressure was aggressively lowered by more than 25 mmHg from the baseline value [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Systolic Hypertension in the Elderly Program (SHEP), treated older adult patients with isolated systolic hypertension (and an initial diastolic pressure averaging 77 mmHg) had a lower incidence of both cerebrovascular and coronary events despite a reduction of the diastolic pressure to below 70 mmHg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of the J-curve was also addressed in a meta-analysis that analyzed individual patient data from seven randomized trials of both diastolic and isolated systolic hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/25\">",
"     25",
"    </a>",
"    ]. Although a J-curve was detected for mortality in relation to diastolic pressure, it was seen in both treated and untreated patients and was not specific for cardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef73430 \" href=\"mobipreview.htm?18/38/19055\">",
"     figure 2",
"    </a>",
"    ). The authors concluded that the J-curve is probably explained by poor health associated with lower blood pressures rather than an adverse effect of antihypertensive therapy.",
"   </p>",
"   <p>",
"    In contrast, another meta-analysis of randomized, placebo controlled trials including more than 28,000 patients found that lowering blood pressure was beneficial even in individuals with diastolic blood pressure below 70 mmHg,",
"    <strong>",
"     as long as the systolic blood pressure was lowered",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HOT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hypertension Optimal Treatment (HOT) trial was designed to settle the controversy over whether the J-curve exists by comparing outcomes among patients randomized to three different",
"    <strong>",
"     diastolic pressure",
"    </strong>",
"    goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/33\">",
"     33",
"    </a>",
"    ]. In this prospective study, almost 19,000 patients (average pretreatment blood pressure of",
"    <span class=\"nowrap\">",
"     170/105",
"    </span>",
"    mmHg) were randomly assigned to target diastolic pressures of &le;90, &le;85, or &le;80 mmHg. Treatment was begun with the long-acting dihydropyridine calcium channel blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    (5 mg once a day). Either an ACE inhibitor or a beta-blocker was added if the target pressure was not obtained with initial therapy. Further therapeutic options included increasing the doses of these agents or adding a diuretic. After an average follow-up period of approximately four years, 78, 41, 28, and 22 percent of patients were taking felodipine, an ACE inhibitor, a beta-blocker, and a diuretic, respectively. The trial outcome was negative.",
"   </p>",
"   <p>",
"    Two significant problems emerged that clouded the power of this study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the cardiovascular event rate was lower than had been anticipated, the study duration was prolonged.",
"     </li>",
"     <li>",
"      Less separation in the diastolic blood pressure was achieved among the three target groups than had been planned; the mean diastolic blood pressures attained for the &le;90, &le;85 mmHg, or &le;80 mmHg groups were 85, 83, and 81 mmHg, respectively. The respective mean systolic blood pressures were 144, 141, and 140 mmHg. This close degree of blood pressure reduction among the three groups fails to provide the power to detect any difference in protection with varying degrees of blood pressure lowering. The data therefore did not disprove or prove the existence of a J-curve.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analysis of the correlation between adverse cardiovascular events and blood pressures achieved with antihypertensive therapy revealed that the fewest major events (",
"    <a class=\"graphic graphic_figure graphicRef55532 graphicRef81362 \" href=\"mobipreview.htm?17/18/17711\">",
"     figure 4A-B",
"    </a>",
"    ) and the lowest cardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef75482 graphicRef71321 \" href=\"mobipreview.htm?19/3/19519\">",
"     figure 5A-B",
"    </a>",
"    ) were noted at average blood pressures of",
"    <span class=\"nowrap\">",
"     138/83",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     139/86",
"    </span>",
"    mmHg, respectively. Lower blood pressures were not associated with a further change in the number of adverse events, except for an apparent increase in mortality in those in whom the diastolic pressure was reduced to below 70 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent subgroup analyses of the HOT trial found that smokers randomly assigned to the two lower diastolic blood pressure values, compared with those assigned to the less than 90 mmHg target, had significant increases in the risk of major cardiovascular events (RR 1.71), stroke (RR 2.44), cardiovascular death (RR 2.67), total death (RR 2.03), sudden death (RR 2.93), but not myocardial infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/35\">",
"     35",
"    </a>",
"    ]. Although this adverse effect may be due to chance, support for its validity includes the large number of smokers studied (nearly 3000 patients); smoking was included in the randomization; and no baseline differences in characteristics were noted among smokers in the three randomized categories. The possible reasons for this finding, if true, are unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT OF ISOLATED SYSTOLIC HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated systolic hypertension is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &ge;140/&lt;90",
"    </span>",
"    mmHg and isolated diastolic hypertension, which is discussed elsewhere, is considered to be present when the blood pressure is",
"    <span class=\"nowrap\">",
"     &lt;140/&ge;90",
"    </span>",
"    mmHg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypertension: Who should be treated?\", section on 'Definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H8#H8\">",
"     \"Hypertension: Who should be treated?\", section on 'Isolated diastolic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benefit of blood pressure reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of blood pressure reduction in patients with isolated systolic hypertension was demonstrated in a meta-analysis that included eight outcome trials of 15,693 patients &ge;60 years of age with isolated systolic hypertension (including SHEP, Syst-Eur, and MRC described below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/3\">",
"     3",
"    </a>",
"    ]. At a median follow-up of 3.8 years, the number of patients who needed to be treated for five years to prevent one major cardiovascular event was lower in men (18 versus 38 in women), patients aged 70 or more (19 versus 39 in patients under age 70), and those with previous cardiovascular complications (16 versus 37 without such a history).",
"   </p>",
"   <p>",
"    Total mortality correlated directly with systolic blood pressure (BP) at study entry, but inversely with diastolic BP. However, diastolic BP was not significantly associated with outcome for combined fatal and nonfatal events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     J-shaped systolic curve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the above reports did not support a J-curve for the",
"    <strong>",
"     systolic pressure",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/1-6,18-21,25-29\">",
"     1-6,18-21,25-29",
"    </a>",
"    ]. The risk of cardiovascular disease generally declines continuously at least down to a systolic pressure of 130 to 140 mmHg overall and down to a systolic pressure of 120 mmHg in certain patient populations, such patients with diabetes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic kidney disease. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Lower goal in patients at increased risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some evidence, however, suggests that a J-curve exists for the development of stroke and other cardiovascular events among patients with isolated systolic hypertension in whom low-normal diastolic pressures are lowered further by antihypertensive therapy.",
"   </p>",
"   <p>",
"    However, the question of how much the blood pressure should be lowered in older adult patients with isolated systolic hypertension is uncertain in view of evidence that adverse outcomes are seen with low diastolic blood pressures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Rotterdam Study involving 2351 older adult hypertensives, those who received antihypertensive therapy experienced a progressive decrease in the incidence of stroke as their diastolic blood pressure was lowered to the 65 to 74 mmHg range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/37\">",
"       37",
"      </a>",
"      ]. However, a significant increase in stroke was observed when the diastolic blood pressure was lowered to less than 65 mmHg.",
"     </li>",
"     <li>",
"      In a reanalysis of data from the Systolic Hypertension in the Elderly Program, those who experienced a cardiovascular event while on antihypertensive drug therapy had lower diastolic levels than those who did not have an event (65 versus 68 mmHg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Overall, a decrease of 5 mmHg in diastolic blood pressure (which initially averaged 77 mmHg) in treated patients was associated with statistically significant increases in all cardiovascular events and in stroke (14 and 11 percent, respectively), particularly at pressures &le;60 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three factors must be considered when interpreting these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower diastolic pressures may reflect less aortic compliance due to atherosclerosis, rather than excessive blood pressure reduction. If so, then lower diastolic pressures with therapy are a marker for not a cause of worse outcomes.",
"     </li>",
"     <li>",
"      The risk in patients with lower diastolic pressures was still less than in placebo-treated patients whose systolic pressures remained elevated.",
"     </li>",
"     <li>",
"      In the meta-analysis described above, which included two trials of isolated systolic hypertension, a J-curve for mortality in relation to systolic pressure was noted (",
"      <a class=\"graphic graphic_figure graphicRef80901 \" href=\"mobipreview.htm?34/58/35759\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/25\">",
"       25",
"      </a>",
"      ]. However, it was seen in both treated and untreated patients and was not specific for cardiovascular mortality. Similar findings were noted for diastolic pressure (",
"      <a class=\"graphic graphic_figure graphicRef73430 \" href=\"mobipreview.htm?18/38/19055\">",
"       figure 2",
"      </a>",
"      ). The authors concluded that the J-curve is probably explained by poor health associated with lower blood pressures rather than an adverse effect of antihypertensive therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, there is no clear evidence supporting a treatment-related J-curve in patients with isolated systolic hypertension. Nevertheless, careful monitoring is advised when treating older adult patients who start with low diastolic pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal blood pressures presented below refer to the levels at which more intensive antihypertensive therapy to produce a further reduction in BP is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. These goals are in keeping with the seventh Joint National Committee (JNC 7) report and assume that the patient is at average risk (eg, uncomplicated hypertension) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following recommendations assume that the BP is being accurately measured. They also assume that the BP is being gradually reduced, since acute lowering of the BP in patients with severe underlying hypertension can lead to deleterious cerebrovascular and coronary events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The goal of antihypertensive therapy in patients with uncomplicated combined systolic and diastolic hypertension is a blood pressure of",
"    <span class=\"nowrap\">",
"     <strong>",
"      &lt;140/&lt;90",
"     </strong>",
"    </span>",
"    mmHg",
"    ; treatment goals are determined by the higher BP category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14,29,33\">",
"     14,29,33",
"    </a>",
"    ]. More intensive BP lowering may be warranted in some patients with atherosclerotic cardiovascular disease, diabetes mellitus, chronic kidney disease, and heart failure (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Lower goal in patients at increased risk'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In a number of conditions (eg, heart failure, post-myocardial infarction), antihypertensive drugs are given to improve survival, independent of the blood pressure. In these cases, lower blood pressure levels may be accepted to permit sufficient drug doses. These uses are discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Goal based upon the systolic pressure alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hypertensive patients aged below 80 years, with an elevated systolic pressure, the goal systolic pressure is less than 140 mmHg. However, as described above, the diastolic blood pressure should be reduced to a minimum posttreatment diastolic pressure of &gt;60 mmHg overall or perhaps &gt;65 mmHg in patients with known coronary artery disease unless symptoms that could be attributable to hypoperfusion occur at higher pressures. In many cases, the level of systolic blood pressure that is reached with two or three antihypertensive agents (even if greater than 140 mmHg) may be a more reasonable interim goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension\", section on 'Importance of diastolic pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Goal based upon the diastolic pressure alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hypertensive patients of all ages with an elevated diastolic pressure, the goal diastolic pressure is less than 90 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lower goal in patients at increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lower goal blood pressure than described in the preceding sections may be beneficial in the following clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14,40\">",
"     14,40",
"    </a>",
"    ]; the supportive evidence, and recent conflicting data are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atherosclerotic cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic kidney disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29031?source=see_link&amp;anchor=H16#H16\">",
"       \"Treatment of hypertension in patients with heart failure\", section on 'Goal blood pressure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79337098\">",
"    <span class=\"h2\">",
"     Determining if patients are at goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether blood pressure is measured in the clinic or at home, an average of multiple measurements provides a more accurate assessment of blood pressure control than single measurements. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link&amp;anchor=H10946091#H10946091\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\", section on 'Need for multiple measurements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pulse pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The marked variations in risk of mortality with increased pulse pressure suggest that this parameter alone should",
"    <strong>",
"     not",
"    </strong>",
"    be used for prognostic or therapeutic decisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/40/33417/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26823?source=see_link\">",
"     \"Increased pulse pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       \"Patient information: High blood pressure in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       \"Patient information: High blood pressure treatment in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19109217\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic and diastolic hypertension in the general population are defined as a blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/&ge;90",
"      </span>",
"      mmHg measured on at least three separate occasions. Randomized controlled trials of antihypertensive therapy demonstrated significant cardiovascular benefit in patients with systolic and diastolic hypertension that was most pronounced in severe (diastolic pressures of 115 to 129 mmHg) and moderate (diastolic pressures of 105 to 114 mmHg) disease. The absolute benefit of blood pressure lowering is much lower in patients with mild hypertension (diastolic pressures of 90 to 104 mmHg) (",
"      <a class=\"graphic graphic_figure graphicRef52231 \" href=\"mobipreview.htm?43/29/44509\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Systolic and diastolic hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials that have evaluated the efficacy of treating mild hypertension in patients with baseline systolic pressures of 140 to 149 mmHg. The three largest randomized trials that have been performed in patients with mild hypertension were the Medical Research Council trial, the Hypertension Detection and Follow-up Program, and the FEVER trial. All showed significant benefit from antihypertensive therapy, which lowered the mean blood pressure to less than 140 mmHg systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      less than 90 mmHg diastolic. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mild hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the general hypertensive population of adults &lt;80 years of age (ie, not including patients at increased risk), we agree with major societies that recommend a goal blood pressure of",
"      <span class=\"nowrap\">",
"       &lt;140/&lt;90",
"      </span>",
"      mmHg. However, supportive data for such a goal in patients with grade or stage 1 hypertension (systolic 140 to 159 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic 90 to 99 mmHg) are limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Blood pressure goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal blood pressure may be lower in patients at increased risk due to atherosclerotic cardiovascular disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diabetes mellitus or in patients with proteinuric chronic kidney disease. Specific recommendations and supportive data are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\", section on 'Goal blood pressure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is conflicting evidence related to the possible risk of excessive reduction in the diastolic blood pressure. Rather than demonstrating a progressive benefit at lower pressures, many trials revealed a J-shaped curve in which the risk of cardiac events declines as the diastolic pressure falls from above 100 mmHg to approximately 85 mmHg, but then rises back up at pressures below 80 to 85 mmHg (",
"      <a class=\"graphic graphic_figure graphicRef55532 graphicRef81362 \" href=\"mobipreview.htm?17/18/17711\">",
"       figure 4A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75482 \" href=\"mobipreview.htm?2/27/2494\">",
"       figure 5A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71321 \" href=\"mobipreview.htm?3/53/3934\">",
"       figure 5B",
"      </a>",
"      ). By comparison, there is little evidence suggesting a J-curve for the systolic blood pressure, other than perhaps isolated systolic hypertension (",
"      <a class=\"graphic graphic_figure graphicRef55532 graphicRef81362 \" href=\"mobipreview.htm?17/18/17711\">",
"       figure 4A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75482 \" href=\"mobipreview.htm?2/27/2494\">",
"       figure 5A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef71321 \" href=\"mobipreview.htm?3/53/3934\">",
"       figure 5B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'J-shaped diastolic curve'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolated systolic hypertension is considered to be present when the blood pressure is",
"      <span class=\"nowrap\">",
"       &ge;140/&lt;90",
"      </span>",
"      mmHg, and isolated diastolic hypertension, which is discussed elsewhere, is considered to be present when the blood pressure is",
"      <span class=\"nowrap\">",
"       &lt;140/&ge;90",
"      </span>",
"      mmHg. Specific recommendations and supportive data are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H2#H2\">",
"       \"Hypertension: Who should be treated?\", section on 'Definitions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=see_link&amp;anchor=H8#H8\">",
"       \"Hypertension: Who should be treated?\", section on 'Isolated diastolic hypertension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whether blood pressure is measured in the clinic or at home, an average of multiple measurements provides a more accurate assessment of blood pressure control than single measurements. This issue is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=see_link&amp;anchor=H10946091#H10946091\">",
"       \"Blood pressure measurement in the diagnosis and management of hypertension in adults\", section on 'Need for multiple measurements'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/1\">",
"      Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/2\">",
"      Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/3\">",
"      Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/4\">",
"      Pastor-Barriuso R, Banegas JR, Dami&aacute;n J, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med 2003; 139:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/5\">",
"      Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/6\">",
"      Kaplan NM. What is goal blood pressure for the treatment of hypertension? Arch Intern Med 2001; 161:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/7\">",
"      Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/8\">",
"      Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/9\">",
"      Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/10\">",
"      MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/11\">",
"      Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/12\">",
"      The effect of treatment on mortality in \"mild\" hypertension: results of the hypertension detection and follow-up program. N Engl J Med 1982; 307:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/13\">",
"      Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/14\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/15\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/16\">",
"      Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/17\">",
"      Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/18\">",
"      Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/19\">",
"      D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ 1991; 303:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/20\">",
"      Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/21\">",
"      Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/22\">",
"      Dorresteijn JA, van der Graaf Y, Spiering W, et al. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension 2012; 59:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/23\">",
"      Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/24\">",
"      Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/25\">",
"      Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data. Ann Intern Med 2002; 136:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/26\">",
"      Staessen J, Bulpitt C, Clement D, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. BMJ 1989; 298:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/27\">",
"      Flack JM, Neaton J, Grimm R Jr, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/28\">",
"      Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/29\">",
"      Bulpitt CJ, Palmer AJ, Fletcher AE, et al. Optimal blood pressure control in treated hypertensive patients. Report from the Department of Health Hypertension Care Computing Project (DHCCP). Circulation 1994; 90:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/30\">",
"      Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/31\">",
"      Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/32\">",
"      Wang JG, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of cardiovascular outcome. Hypertension 2005; 45:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/33\">",
"      Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/34\">",
"      Kaplan N. J-curve not burned off by HOT study. Hypertension Optimal Treatment. Lancet 1998; 351:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/35\">",
"      Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/36\">",
"      Lund-Johansen P. Intensive blood pressure treatment: beneficial for all but the smoking hypertensives? J Hypertens 2003; 21:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/37\">",
"      Vok&oacute; Z, Bots ML, Hofman A, et al. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension 1999; 34:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/38\">",
"      Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/39\">",
"      Shorr RI, Somes GW. Can Diastolic Blood Pressure be Excessively Lowered in the Treatment of Isolated Systolic Hypertension? J Clin Hypertens (Greenwich) 2000; 2:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/40\">",
"      Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/40/33417/abstract/41\">",
"      Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160:1085.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3861 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33417=[""].join("\n");
var outline_f32_40_33417=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19109217\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYSTOLIC AND DIASTOLIC HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Benefits of blood pressure reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Severe hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Moderate hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mild hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Blood pressure goal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13441432\">",
"      - Goal blood pressure versus achieved blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      J-shaped diastolic curve",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Positive studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Negative studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HOT trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT OF ISOLATED SYSTOLIC HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benefit of blood pressure reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      J-shaped systolic curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Goal based upon the systolic pressure alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Goal based upon the diastolic pressure alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lower goal in patients at increased risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79337098\">",
"      Determining if patients are at goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19109217\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3861|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/29/44509\" title=\"figure 1\">",
"      Benefit of Rx of mild HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/38/19055\" title=\"figure 2\">",
"      J curve diastolic HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/53/17245\" title=\"figure 3\">",
"      Aggressive BP reduction in CRF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/22/1390\" title=\"figure 4A\">",
"      Systolic BP cardiovascular events HOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/50/2862\" title=\"figure 4B\">",
"      Diastolic BP cardiovascular events HOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/27/2494\" title=\"figure 5A\">",
"      Systolic BP cardiovascular death HOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/53/3934\" title=\"figure 5B\">",
"      Diastolic BP cardiovascular death HOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/58/35759\" title=\"figure 6\">",
"      J curve systolic HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26823?source=related_link\">",
"      Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/27/25018?source=related_link\">",
"      Treatment of hypertension in the elderly patient, particularly isolated systolic hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_40_33418="Lngth age boys z 0 2";
var content_f32_40_33418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64985%7EPEDS%2F76745%7EPEDS%2F77428%7EPEDS%2F56424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64985%7EPEDS%2F76745%7EPEDS%2F77428%7EPEDS%2F56424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Length-for-age boys: birth to 2 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 399px; background-image: url(data:image/gif;base64,R0lGODlhXgKPAfcAAP///60yRNMhO1lZWXKLfZeXl2OkgaxMWkBAQBAQEGBgYNY9VKNWYpCQkHSpjVBQULa2tpK7pTw8PLqlqB8fH3t7eyAgIFaadbPKvRaHSuBUaQ99QjWKXeiosm1tbSiOV8YnPomJiQAAAC1uS5NbY3BwcMLUyi8vL923vOFhdNZ9ikOTaLiWm87Z08U3TNGrsblpdUlJSWJiYld4Z+Li4laIbtqao4m9oZXDq5d5fTAwMDqXZYmtmtRufe3HzUdyW4pCTbm5uYVydaWlpaibnXm3lomekyoqKieTWtUvR2ZTVZs7SV2jfTY2NqysrJRuczo6OoWFhdXV1eGhqpmZmVpaWkZGRqmpqcXFxQcHB4KCgtpabd6EkcODjGpqalVVVSUlJV1dXUqecYODg7+/v8DAwICAgJ2dnfDw8OUZN+Dg4NDQ0A8PD+YnQ6CgoP3w8u/v7/WotF9fX+lEXM/PzwCFPu5vgug1UO1gdbCwsJ+fn/rT2fvi5vB9jt/f309PT29vb6+vr4+Pj/jFzetSaQ+MSu/38va3wH9/f/KMm3h4ePOapy+bYh+UVs/o2l+yhp/Rtt/v5m+6kk+req/Ywo/Jqj+jboGBgX/Cnr/gzuDT1cLCwtLS0tLa1rKyst/FyW5ubtbW1qKiotuosDIyMpKSktiMl+fb3N0eOqiPk5ycnHJyctBEWNnZ2Xx8fMjIyAWCP+VZbgiFQqLDsuuSn1GkeNaJlGVlZd0rRchiccZUZYyMjNJSZc+co7GLkHV1dWWvh+S+w8jg09hMYPLM0u6hrOA6U+FIXt7R04K0mZykn65fa4t+gNpoeNNgcefN0dK4vNx2hdknQUxMTOaapdFeb/X19cXNydmmrdnh3bnSxanKuds1Trh4gsSRmaeAhojCo+3T10ijc6VyenyVh+l2h6W+seeBkG2AdjGVX+CUn0Wgb8UsQqauqrmGjbktQUmAYnJ6dp6zp8pwfuvr6yODUFirf4tkavG+xZtob8t/iuKvt71wfNPHydzDxr6xsyH5BAAAAAAALAAAAABeAo8BAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnftyjN27ePPqlaG3b19FoPwKvst3sODChv8GTtwXMWO8oBQ9zgt4cl7HliNbvlt58xhFAyR71uy5s2fMk0mf9mwX9WPVm10zlp3YdGzWYwYstqxUC0XfE6U4+U08+PCJwCU6kWK8uHLmEoUHHwA94vLmyClez879ufOIySNK/+8eccDxh+GNpkdPcbzE9Q7hN3QPXnt1iPQhyme4Xfx5/NRN1B9+/+ln33cGCnhfgu+1VyB7E5lXX1L7LVShQvlB2CB2G3oX3YPxHfjhdAs6NOBDGYaoIIIaWleiih36x6JDEjJ41IUJ4YhQig3peJCPBvHIEJAFneiQkBaKKGN0AXq4ZIwQGQnjhE5SaSWBMzZUY4vqZckQkgoRSZCYA4GZo5JYkhfli1+C+GWTLnJ45UNS9ujlQnUOeSeGbuoZYZ8IkYnTJTQUauihiCJaQaKMMkrGGY1GauiikkZKaaWOQoopo5dueugZZHiK6KOiKlrqp6GeSgOpqpIxQKqngv+q6qqaqtppqbLOequou3qaq62z0tDrpqwCO+uWAsGBCAIIAAKHQYLeFG20Zga6Z0LV/ogmioCGue2R3e4I55py2kiumlzSyaafUHJ7LULIAkAGGwiwIYIc0Pb27kHZ5osuuPsalCefARe5LsFMHpzQwNiGa+2K/9oJcbtTpkmxlgXC8SwZIvzhL1LTOljwmCJHzJ/COzqs7cQWA4jyQQynPPJAMT988ckzC0Styh+XByIgFFBAR89dmrxQvwWFXG66Jr4cJM9Jfzsf1GWOq+7SFV9ttLcsm8v01DkDEK9AegByL9FFKT3i1mdiLXGV7rKNUM1Pk9g1wHLD7DTaWTf/HfbOOfshQYF+JCuCCHwPRaiuwRZ76rCYQl6p46VKLumvpVLOa7CYi6o5sa/O2rmnn29qeaSje3p6o6szmrrpwbaeaOmRl1rKAwmIkEAgBSFCLwUiIJC4UGo/OWffYOct8N4EIU3y3cmLZ7Xfa9+MJ/PPW68Q3cMn6Ta7CfkhCAIisCGHHmhUUSAdcjCLyLNRUxi28wMV37LX1BuPf0PcN0+1QFKYHv+wB8D/6UxqbzveAP9WsovBIRByAB4CBDG0gYzNeyCbnwEBYL+4aW9hBAQA/Q4IvTbZDW54++DcQsjBsPUvewo0oZroMD4RUEAOgYBfQS7ItQwqryAjbOEP//3nwhAGMVovLOAJ41S9GF6PgSUE3/5k2KAHAi14FFwID9uGlMUZq1W1elzsGhfGynEOVpkr4+ZEh0bPqRF0bfRVHIn1RtixcYyMu2Mev3gq2klqDVYgXwIQUApOeGqLNrtJGdQwEDWU4ZFr6F4P9fc1KXrQidsz4gaRqMklnouSyMPZEOuHQEuG8mhQC8QVLZBFn80JDWVAw0Ae+UhZmmQNFjADAhogEF2awQxukCQXQZnAKaKyiN/DIBOJeTQBipKZyvwkJocpTWNO8n4HEd8fbIhDOEQLkSsbiBt0YAYdlEEgIvilGRhpEgUEEw0JkOUvqVnJY46ShE20JgiTef9NrUETW858Yj7rmUkoovCU/UyhQVQJvBMgooL4dKW5LMDIMugAnStBwDkBoFEA+HKj8VMhvzapQWQOFKH7POmbQphEEZI0itEkaEpFKkyZEcQPevgDG8ynBx3CECLgJBriMAqAdDbAliYZZxncYIFzPjIPOuBlSKdpU5pOFZsoXSE/6Zk/rK4Upg0zqVV/6k+qhnNJZADECUTgUIgmEqhUS48CFFCGBgzVDWUwgwWQWpK8jpOdAimD8AriAScY9rCITWxiC6vYxiq2AFpwrGQPy9jJOrayln1sZDPbWMxy9rBaKMBnEwvZ0S7WtIgNLWoNW9rVFmAAol2tal272dX/ena0s7Xtag1728/mFrW95WxwM9uAacRgp1ZQwC4+O1zLDqC2zDWIG8yQBwsUpKMpEaxAbOkGBdT0rF41ZTEvqU+tqlS8zwwvhgJa0PPGtKvlBW9Z4/vdgdABEWulACDIMFYLxhUh80QqRVFSghLoIJIAeIACSmABBJM1qyM16D+5ukD3JrTCE+YXe2eq3gunl75Xna9M34qQB0awY4KAwEslcsFBDIIP4F2DGRSAAFniUpfeRUkZHCyQNYA0xBCu2z2FaGEKf1ihICZIS0cYQJZ2csgtJbJZlydhg4iPfDfknRKHPLY2pOHLcSAaLAELgDHvpINIHrF80xxkg22V/8TwZfNXD0rFKbt5yJysskAYytZWEpHLD7LDIBaRhjbU98wlxXMD7azkJ/dXIEs2YJPBWlVG04yFaMawpfEJh5zu9Hw+BeKKJWqQNxT60Drxohhn5UdJyc5UrK5j7fTYR1lX6tWoijWrQ6eq103O1q4+Ix75iKs52tFWnpBBfgEhCjoO21OasEEKAuCmRKQhEajOSabrnGRSvnnNmiavmqlcZA07+dvZhjSmxWppVebuAYIonLghPIg+zCENd7ADEEBkbTuAm3iJfrSUO2xkgWb43wYnuLkpHWEor9vh+8LpNtmggAeEWs7oBcAeFoGHQuMhDjAWW4HeYIc0EMLFb/8A8lC2bU+BAw7i5UZ4ew8OxA2bl+YqP3KbHxxugt53rW2NqMLly4c42MHLhEjEHgwSr0F8+emDyHlQWI4wly+62+pGt9RnPvSanzvm6QZAlKnO4f1BEHh/iPfWw8qdNxyiD3dIwxz6cAiFxOsNLs57ynkO8CEfMeCbFrujAx9pT4o4eoR/uMDHftOcclPLMme7RJ6QCELg2w5x2LsW/5sUVZtR13tcNRifXWzQE1tUvpZUqxvlKmNXKvWRWj3rhB36z/fa9bemgScU0FBAvGLWoxfVJ0zBClS0AQ+LIMapgrp2n5C90lgf+LzHG2fER7/wCWO4kBev+MRPJBA6QLv/2ndepnC5He5yT8Qgvsl5Hwr8734fdTUx/t6eW/9INteb1vme8Ojn2SGdplNs0AQ59H59MgiJcG/5dgiax36BZxPP13BWt3/eRmct531g1zz5R244x39c53+lZF+CsGxDE4HbJxB8wHFtcHyLEHLNdxDM54E/YYKipmf052H9d4MF94E6uHAWWHUYOIEWmFYSNH5CN241eH5xNwfqV38MEYMVeBSet0bBd3qqQ0akh3q4F3vAZim0V2u7toWNAnus14WzR2uil4aldyitAEFskAWkoAWGlCi4NinB8gK5YHnSwAumoAlXeCztdyOAB4IUeITVx21I2GiFOGk/KHlB/xh4/ydxj+eElGgQRYcHXjYMi7B0gQeFhrhyg5iIUdh1L8iBpCiDN3eKALSBd9aBo3h41BeL/DEEI8hWD0V+n1gQb3dvczcI8MdigVg0BmiD94eLgleI0neIF4girKiIGYiK+qdoEUGEKCZvopiLG9dxbYB5LviLpGaMEBiKxvhy3IeM/+eKItSMl2aOIYiD7kgQbmg+CuBWhDgQbmcHcZd0nFiDgPaANUGDfyaE6JiM9oeIxoh90vN1A3mOkLgQATiJxyiNe1B5l8eAQBh9nkiQQjGFf1iFakiFYFh7Wmh6HylHJOk5vBYrYpgpWWiSItmRiLIJIQB0VeAJiEKGZ/94KprAAEeXBrGgAihAOmbIKcGSkdFSEjIWTOJkBj/2isbojdEHlbC4jNcYkejIiMukirmYg+NYEHSgVn1mja1oZ/V2bwJAd8/olBgzJ3nAlI1kBkeFElBVBiXwAL1EV+YUduTYkOyoffxYjmmZjgqplRrJlbLoPXz2Bz1lmBmHgnGAiccHcnuJkcFYAnS1S2VmAXnQAINlEg+QBwIxYDrASG5QAnp5dVU5mVWJkI84fc00mK5ZiWVXlWEgB59WgAWJXmUpd30QdWppkIdpd8EYTwCgBtaVBzm2VyfxmQLRUUOlXaUYnQHJl4FZmDxYjME5m9j5mn45ndfXfQzxkFn/oACQN5XRdIkr+HEuCI0nSJlXQpxF5VFm0JxNKRJlkEsK0FTxCQDQyZ7SWX7ECJyNqZ0CKpupGJsABZs9GHkHOmJXZkOAsAZj0I5ts5tzt49wtp0GCoPB2ADkpACIM08cVZ8iMWbKmQCBZZeEtVtO0FyT1Vq6tVsuKlkwClws+lujVaOmNaOOhaOfpaM/Clu75aOcBaTMdaOxFaOOtQsSkDsnEAVuQFlIulupAATvYHx2oA4TcKS7ZaTCxaLPBVwG4UhrcFENMJ8cxWMm0QA5xpwlIFX+GacAKo3VyZAIuoMESpXzoY5ZV6cUCmdfuVYTJJZbeZ0JsZtJ0AcY+pTy//cQRokQDxBMZVpmKIoSOoAACmBLZcosfFWoeAp9qYmaBzl437mIfGqVhGmnLUKNinlxv8mYA4GekckHADmnAveoBCFYCICmAGBgOqCUOFGrWyaQqfqn7bmapIp/Cqqh79igIRKP3TSgzioQe2BvvOmbnpqhBdqsHOqPNCGsLhWgepqd0zqu0hqNV3mqrFmqEhEIR3Cb7GqPRpeeIMeg9nqsxoir7hd4Usmo7Han2gqrjsiMy7qtn4qu4el4FCAB5Yms1JqA+IaW3Bp2/bqW0WcTHHlsIWmFGptGLbkpODk7Q0mHX+ixrZKSa7ixJQmyYsgJWkAKEPp7dVgoM0sDRP/QBbwgDWmAfOEAk7ansj9bKvoqiPEnrhfpsH7anbbqMko7rK3ZeNukX24FkCnYcQtIrAB7rzsUjGkjjuSqtd6JtAtprH/JtI0IqqNqZbV4AkYop9kKAPW2hIvgC+BZlRX7hA8iCYVQB4zgCGEXjkVLp2PbtOEKc+lasOa6oRwoPkDXtqeZEG/wmCuIeXvHeIF7qwUCCXUwCZRQB43wt//otedKsY2qjEebtoGJlfPHrAe7PDTUuIQasAk1kbzYm6ZYj4MLjAUxCXVACQDACHXgt257ExkLfEALkkHrRh+LKSE7KiMLa7d3kqSDsiPpkcm7Ka+AOyIQh5twvRp7CPj/mAasoAKfgDorSZQv6WzpiynxYgl1kAkA4L7wO7yAO4yCW6yEe7cCi7ZzlpVZe2hfCTw6sAudOo6XWJGal6eK+59O222ZgAkjUCDyG7/vy8DSIroLPLz6a6iJO7Fj+b8aiLinS64B3DE9ZbkQMZFJkH6Lur+y27plW16GQAmS4L6FMAkRXBCSUAeVAAB7awgWXL/8Wrpfi69F/MELGnbrqqz5S8QCUcKtuo7KA75xhwcMsJ7m6cEa7MSRAAmP0Aie+wiQILzxEgmFUAjAKwmg+60YrMWvOsKji8Ss+8LlCsfrJcIDyzRQvJhyHJwHfLXWqcBu/LZGLEWOUAmTAMaM/yAJlBAJTPcgkVAJmOC7azwT4LrBMBy2qJu7/pvEIdzE37HHrtqnF0O7LGzBKDzExPHAlrC3loAJmQDECTG0RlG8uSe9Pou8yru+r3e+zru8vYzLmNJ6aLjLwOIJVxQDcsi8vgy9hTIF4fuT5Yu+0cvLwSbMkdIJOIAJ9VAHhSAOBjALokLLXXu51MnJq2uwdIywIFw1eMy/C0EHEkABPDXK7MwekQuZdmCRg4yquKtwkUDDwNsIj1ADwvuNR6wTl+zEGby08Yq/ZyuBZtvJc2xfVwQGfJzOC8EHB6CAiiq25xxeXfzFYQwJjhzI8MK1RLHQRpvHmwzRFK3OQaKuyf96EKKsqgpRrXGXBC0ImFiLZIecyHzLyLI8vOS80m2cyW/s0gktxeicxfB8x6CcEKK81HU8EOBLr28ArqkclcMR1K48yUUNtv7lrZac1OtMuv/qycO7xHv6zhJt0WiX0VZ9z/Jqtfs8vDjd1IRMEJkADB8Q1vPL1yJn1jJhy9dsvbqcy0IJzJfTzIYie9SsktisetTrkirrCVWAdg0wh5OdsobyCSpgeXfQB0FJstZsvo7thZ4yCwZgwytwAeLMseyr0jLhBgjAnACA28ximhasml3ZlxFdyA1NylqpulAdYYxrwvZc1xxYrbzY00rd18740wNhCKzszZNQCX6LySn/fSVogGMIxizMoqYi4QYPgAbGyUgiStbU7dChKtwx3cHT7c9svYpwbRBlUAVrFcWjSsU7m3mEvddxTFYzLAnAe8PcHcNVScsKMJ/3SVQp0QAqemDyWd/APeCiSthuzeE13b8anU21CAaO29RutwVYys/BPdyPe+ADLcYnHdcNHowPwEvwJOEogQYIYAEF1ksIcKlk9t5CXrjWLdNK/OEF7tTHTdMN0WmNq2IBk8/4pgtT0NJXPd2GUAMIXtIxbsf9TMu4lNugCQAWsONwWhJ5kN5MRWYUbhCKIAVwHudyPudz/uZ0fud0DgEFgOd8Hud23ud4/ueAnud7Puh3LuiG/x7nBQABiT7net7odQ7pcr7okg7nj17pEDAAjF7plM7ndOB4CXALm37plY7od/4Mi3BvIKALLyAFnV7qlQ7npp7ory7ps47nLSDQdbABHOAAGCDppG7rsR5Ahd7oilAQb6oG5UQQaNBgJ4Fd7c2fnTkQtz7o1Q7owQ7p197n287n2W7sw17rjf7tid7teC7uiU7ug57pmy7p6A7nvwAGEIoFjl7swo7neAgCcrcIzzDp7X7vsB7r727o234NPLACG1DSLWDud67u1j7ssGXrBTFUI0oQ2FUSZpDeaJCXDaAGaFDjj5u09uvTMB3iTM2dcOOGUhvV/aTTAZ7ASv7Pyf+9Zi7O5VscNrS8qwCAS2iwBsFUBpV6Epyp22mOmSH/1P5quCU/8wz+1hADrfzl5VyU1ZEJ832c5EOOwjVP0Cad1k1P2LSMBiWAqZEk9mSv0Gjt3igt4y/dzs599VLvg9YxBEBjPg178gvBDFSf17lZ3Gt/u+ih61zf5V6vyWBv23038iHt9lmP5H7f4Sj/EH6ACHPdgVJe2nVn8hhOtgKR3YUA416N84gfFIjN2orN2B1rzCvLzJWd2JR9+sN82Y2yBrVICg8QBK1vKKfwmGkgDc5wDyXrvcYL2pGS3bLQ6+iw2mWo/Ixy1KBozjJ/340v35rP9iB+EJ1GPmxbOJD/j4Kpfsp/D/f9TOBBrd0LPuQZjvWFfbGhC/3xLfLzHfdq3/0JmhAKiwhi2eEpGN1YDBBaAAwkWNCgQSdSDi5cKJDhw4EOITJMaNBRpUmF6ljC5KjhxIcSQRqU4mTkx5MGB5hMCUBkS5gxZb5MSfNkSZkuc9ociXNmzooxfcbkCTIozKEtpQxQaDCQHDYUANFZeFQpS4J7Fs1JM2cRH4ZFJ1ptKRai2YcVI0F6pJFjpolow+ZMWjbnSphyc+7d2Vdm3Zp+hWLNC7QpUsJ2ZZK9mfgmU4J0AFFgIycQRMY9We7pcycNnjhv4hoWXDimIQdiGtVhJIlS4J9/HZ/UexCv/2K+uXUTrG2wd0HAtEtfHZ4yM8jgI38TPD4xuXOmfgRREPFHz8jmEKX46vw5tPDFh00TTWmIkiRGdTYAo2SIfOzBxU/ehr3b/t5LNPTv59+/fwX/AgyQjDMENHA/AA80MEEFByywwQAZhJC/M8iYsD8CL/xPQwot5JCGDD8MogkwRDhBC04urJBDFLqLxRRNOJRQwxU/pGHGC3H0bxZMLKmjkVqSMaHGD3WE0MgGQyzSRhroA+8+KMeTkjj4pkzpudHCk00+7MS7cjaIAvlDhCwq8COm7ArizDM8bJmAS6O8rM/KgS6apI5CJqnEI+bkfJJOzeCcyEnlojR0TtwQE//0LLrABGm5gdJkCEtGtYxvJDqgYgOQIaoIxdKH1mzDjkNEozQk0qpMdK2MNuqIIj8LVfXLRR8ilKBD8CAEjz0KgvRQ3X799dS5Zm2sVli3NLZLZR/yY7LKLgNgqVjHivUQO+4Y9RCSHM0SzWq/zcu8R1ZrDS5rkUXp0vdiunUgQubgqg3RIgL2XlSXRc7bSttVVN902QU0zmYNgkOQE6rTAw7gIAPXIGzb2HZSfvN9GGCGMsEkgx8fac+4cPsd2LmKi3UXTLAA4GoQ3vB12Td1DyJ23ZG1K5nmliRdaOaDftVZZsf0GPMEQc6U2WGYgtrDDolJJTlmhEK2eCI78Zz/BJ5IQK15air9bem2NwYRO2UA3pC4Xp1eVjs/G5FUUEkZmXT7QLg1nNtAIjWsO0cm875QSU8eiAoQT+gewEMOz2ChGW3tmGLCvSe8W0C/+Tawk2RqWY0jDPSbPMDKJZebyciPZPK2QdJQPRGC7EgjDl/VVlvYRqGOveBEc5Z655t7ThUxPxChzrKekD5JVKe73jpZYzNBjzXX3Lv9Yq8RpRXjhfaIAwgw3+AK9ullv5d23K3/U/ncQS7/fPVhgiMEC0RAYOErjYdozc+62R1o2/sUrOpCPAISWTNZ0vbnO+xRDFna6wMhVEeIAIDJM3cgBCHAlzbxja9/A+EZzBLI/7sNAuBn3QrhCAEQCAWIIAEKMJpS7HcQ/IFGNCYkSAfDp7ucxIMtm9uTrKi3PJxdr3oDYaAD00CIPsShVwB4FwAq+MQL/iqD7KNioD6IQIGl7yQ05GDvPPhDZ0FLDnQIhRdr+EIidkeGBeHitMzYMq2NxHnpaUT0tMisK37xX+3iwyESYcQ52GERS1SJGaU4xUeF0IZwHKIVG0mwLJoPjww5WMKsU8M3Tst+fNiKd9DGxgMCJ5MYNOBIIoGRQuQJEgQoYShvKMl9yYQPJPhjG7oiSJYNypCIBBbblmSj0jXoc/4ZJoYe9MsPhS5Jx4ybjZRZClKYSBBrMCYwD6efT/+oIAlHjMMpDqTMtzHTbn1DnH86EYELcIwRmBAGgkbnzHKOs22kE6eBNDGKHrACFWnABS451ESu8ZIhaFCADnRQgoGsQQcIQAAasAhE/uXxlceSqP8iWUVIRgZaU1GgUAbQj056hWyYcWUXW3mQi/ioEQKU3kR9WMqK2mt9AwlbIvAwQTwkYhBv+BVACwiANTBUB24YSAkMSlTxNQChANDBGgDwgDwAoAQNeOgdYxlTUqIPlgHbI0SjNhA46MGS17FZTN6gjnd05Ss4vOhL2WqIHW6khwHFKFe96tKrEmQQi7DDvAih009mNSU+xRlUAYCGBABVB4dNrPjcoAM1AMD/ApFtbBkeUNWtlhWrwxqlz0rqxlY+RQQUEATD8gqSN8QBD/wMgD/iSNFHjsUcmKCja+oqMrbGFrdfYiBXjpiIQ4wUs/PZZUEUoAA0qMECAGiAGQaCAKeKDwEGdS4ARDCQMiBguG4V4l0Z2VWr2rW74XXWAxKQgDFqdSERu0Mf9kCt1zryrnBtSx30RMDM0nWS3pVpSvqYiGOobg5JJGQiZULYqqrBoBYoAwDMUF0ENFh2DwaAght8XQBk9yAecEKHPfxhEIOYwyEmcYgLoIUSp9jDI1ZxiVncYhOjGMYkfvGMPayFAtgYxCfWsYh7PIQQIECF0+ixh3mc4l4wDRUB//iGkQeQ4yI7AcdRdsKRo1zjFMuDtnWAxQh+AOUrU9kJWLbxlKlM5hmj+cMT6IVNbSmAACyBBGJWc4sHIGMde8AgEc6wBdBAYQDwWXYIiKqDnQtZALhhqXgVl3q5e9uHLLK/MAVvfgeSqaggwg9O+NRFkcctkqAxo442MEPoq5FJDDBSnxUspJmnW/1qpa9paENOd2pSrCJYj9Z1aKDLkAcFDMTP4suDDvKQh8k6WAFl0IGEGb1b2PK31fIlb1o+K+lpE+RgwyODRbvKSTZd8GifbSO2beKILZ/rIG3MdqPbB2uT9bGBD+xDcEGY6+ISpAQPKEMDFosGC+ShAdrN4P8azNCAyA7EDWZw9rP1e9pq/3S8lq7KtTv7EDGZiH6g3NIbQvod7YhavNHGzantWwn8rpvV5AMjxQ3yhny4+ZaDhLjLC2mlPJjBDb1Ww8F7LdBSS9vcirx4fGvOvmdRhqMVlwkyYLBakT6G3BbfCbpr+5pRRzyIW1x5SrQ3a1TYOrBPw7e0gf5wd5Pc5g7vKLyZ3tag60HI8xv5RNjrXqSInKQzfQi5OHbf3Erbs4J6gx+NiMQ48IGzIWyiIP6AgPR+9+y68WUzPxRMBRWTP5rfD+YPxHn9gJNu9RSdJwARFS9sAkKi50+LJJYCd5A+SddMZjwhJ3v/mAAcKq3FD8j/+U5kJs72ousPCmiRrTTcIRYqGMWGgIn7zJ8OTPKjDgXYPnlXb53aa5f8xLOvcr5DBA7TsKS0uD4RcH8G1JKGb8u3b5Dz8JBPg9/s7wpT+D8+ELhj777av3/zhTAaEWCD68O+oNO6iHK77Tq6R9sv74OITDkvTXO/sokDrrCgT2I/vbO29YGrjAggSGipSQs8BNy1d/O6RXCBCRKkAoO292vAhYADMkCEPziBBGAJGSQDMjAasRIB82s3A+S+EXzAAxRC0MKqcruZsEoYOSCDMbC/gciV5FurBHShqSsYq4MedNG+rDNC+psI/Du8AygVBSQhgKGDQEAEBKg+BECE/0CIAZYgAxGYQ0QYiBlkgxMwLSAMQhhMuxcswv8TpZOCO4IgA6ggLdP6wqWRGLyLtExqP0ojDkool5NLOYk7v/ozOgCQtRWkuT28xD9sNDIQBEAQMhORA0EgAz1kotmAA9NKmG4bQj4UvNrJREJ0wS78w20TgSY0Qa5Lv+Qhu7y7QpiIhBvggI7BukD0NlrUmpoiBFtCInvzxT7UrJhYhRn8A+pgAwQABD2IRYZ4FzlEgIRhAz08pFmsPHm6POj7PODjEM9bkN9jxwARhQcwkRBIEWKyEU3ghwU4ImqIkduzpuFrENbjDwwwgPT4gAvonOCjkYIUpneEyE8whWaYF/88oIXmc8d5er4L2YRSkAEEYIPR+gNEoALVm5B3gYNShLwW+sRZRDtcFMZmvEWZ5ECB2cVevEmIYRoBOAfhCsVI28BXe4hJXI1Ui4Sh00Q/BMSJ2KthwIWuSKKg5EkupMmDoAM9KMU5PAE5QAQycIW7yLeYLMMCNEOz7D+htErwuxRDHK3ScsqD4IPOGJVBSMK/IMq3OwgPxBOPaamlpEC5bMqCCMMHygVs4L/BnElrtENBkIOEkR9vBEdZHAldO8uyxEy1ZMDFZEu0lLZyU4Ue3MlqTC2uAA1mJMKQI0aCuIj0aA0++cwS5DhbnMs46AOuuAM88ER2YzmkUIVsLMf/NtQDqvDMgrjMzcxMxjROTAqhxUPCkqKDL8gCRBwYbJlC4cJLjyJG5+EhS5RNI+zN4dCKm5rKxGvLtKxMhvCDbGRDN3xJwoQI5FRP5WRO+mzM2UxO/AzPA1pCEYiBXSgOumycFkxN/0MOvVy3CGgLVRJBRxzE9NSJQZC5vyJDnIxQs/CDNBzJkkQENxgCxiPL+hwJdbQceuzIh/ybdpRHeIKQTXgA6kSEVohHAWEQTTCFbQINBTlIByFIDcEcZFwpSoDHFa3ReUxRBdEEG+gBdqA1W1ORiIw+FN0PkFQAMMiCDiWDVui8Io0Q6TO7mPRNUotP+zzCCE0TuasO8xu6/0FgmjugwrrjzNU0pUp4TUkwAqqDTmSRt9zEgwMoUAf0QgDQUDUkSa9MxQctu/xUTjFVzeUERTl91L00iOBhAzaYQEGMCT44gMbJJUystOIJF0d4HkZAuVULP0lFz4HhgzhAvjuwg/MEgCdkylQdCEK1AENFRcrcz2UciPmEyRG9zzINTKErupYjgzGhu3tLCdVKgyQAORI8UOjwk+60rxD8KpuE1Dg9wK/zjAGzUM08VewhVA71SivYVWkl03AU0WCt1XA105oE1Wq80G2rDPgET4bgjDZoL8WDwnQdSvGYxFRiqaJ01DIVT/K0pW9VTGEtWPMh11xF1IZdVmn7Vf905MMSJb4TRVLT8cgphUgaeAWoSAAUWSYFOQULTANWsAF3atGN1ZvDyQZIyAhZWIEIMMgoNRAa9VKX1RBiSEFbcoEe2MiOrb13mlEaJMkEIAUZEAUj9ViObRCLbVeCUIMyuNroetfnxNBaPFMzELI/QNdEXYg2ncLA+sIxjbQR2IEfkYTYzMVIPdj92Ss8iMYD8NRFFaGSkkEE0MYsXUVt5dV5Xdetudqr/TmQSKE5FIHqagk3YCgEsADn+toHQyqt7dp4TVvmhAPhudR7xUoAADe7DNwL1dyCOCUfWY+3/VTTvcq9e4gJPTydmtgF3FaDGEXIHEALcEPA7cy2q1j/ES0ByE2AC3swM0g4kCgDEbAAyLVcmeAzQHPdYTXWYoWaTDERBcjTKIQ6aJVeh11LADil16wEDEhQbJVX353UgYhdJ/XEy9VEreRK+XlPYKXGuCVdwr0jgHMoDGsJNRCBhtuLPCA4yg1g2rVf0O3V+s1Ut0vTXsRLPkgEAh1c9U1X8WUNU9Uk1mzd2n1d9q019/VeEVZVcp3DbiTODp7eEAWUEqguxm0AxAUJyn0wA04JBsOuX9MBqkJgd23O2uRgHuZcysBUvf2LblgtC8pb7bQISUBKVWuYDTZY/F0IFlCBugVhQB1hHra29hwtXVVXLWZg4KUTNUiAXnODMjCD/2EbiTJeXMbNicc9CA0ziDpTsTpOMSsrsjt2MTHL4x5Ts12IATxUgBAzMx1LhWqQmGpIhTCjMkPusTwmhwtYjXW4ADcosQJ4MkcGM0jGMz3usW+AAQ2wpWPIhXFoZFS2MVeoghgoETawgi/wAFXIMzrrY0/+YzG7Mz1eCAVoXIIQtORlXMNFXpi44YE442Db4imuwrzdWjohA7AV2yI+iThwIEKwBeqN1kAZVSd20HGj1d+ttoT9rbvsunENBPntxmVzTszN26k1iDLutZ9LtpMYqtyIY4J4AAUoAQvIWv1U4R+WYpzRA8qQg8810LnsA0YEC2LVZpDAgBXoZqkDZ/+KvSNWrVtypk2uXYhR9FsKQMXinOaNztYwJoh3Nq7GXQPJRYBkPgk3fuOYWANiBqoaXuB/DmdBRdV84dxM611VPYhq5iYxVuJQ4uY62IFrtUKKZuY5YVXkGzC81eia9IOtFE6w9GnxxKqGHix2LQPERYMymGmQgFyGcl5gadR/LVNnLgs/gIoTIKtADd1EWGimVmCdMepUu4ZHNF+pFuieKbzuWFjb7eGBUICkPUUUHmy1bmcjPOkoWQOnstrZITp21mmOPgL5kebSBQApTGKctmtRbWJrlR4NjOK0PohB6INtetXuVexlpmpASJgsMEnN/l4KTuHPvm0ANMKJQAP/EaCqNRABsz6UjC1aIp1IEz1uDRGFJhCBJkhJ4cOmaNCWPviEcELuCQkdDGACpMSBTqimy6O96H7ZA8EnB6o1BrBuo/1Y/xAFGRBkEwGEBtgE0KMBHuXZqL1u9lZJdt0N5f1lXz5ryg7o0x4Igt4UP/Cssp0DcRPc9FXVSBDtVPNmXBvGpcZXguCkK97NJULb9NHQ2B5A2lbmClbgtW7s/taN4HYqgNthfEFr8C3pAx5qhjhwREhEmXgDfcCFUcni3H7wr7rgCU9gBDXt7XNqb51dEv9p2KCDx6w+OUhsGRfpzPXrJd9tBQaJ+IlcERBrQ4Hx+53yEy8InqaAjZtx/z7wSS5g2LGVNnlwgPSwhKQO81Az8rw6BNycSnDF7RKfCL41xTYMBJ/mcyY3ccZWYMeGkqBa3uE+FDAnciB/1+Qoc7guwKDGg3K27DCGq/H9TkifU8HUDl9YhPOG1aok9POdCNhOGArQAUEIaf6sbJJG9eNMcaq9cknPZiMEDEq/yTeQ4DZIhJRZYiDqy1LFU02v8wsP3Va1JQ4HzXBxcr/1Sj04k0d/3ZFGXzC2DVu/dYIobomEWssbd71hJk6QgSx4aykVEBTgha6Ig/64b/DOb/2IgBVo23ay75wVkJ3FEPEG2QaxAWfYpgHDhi7dx57dD/cukfkNhC3dPOxevf99f1p619mDd74PSXRvp/WbruicvhSeRoDaVsugtoOoFldtx8VMYFC3TXUrPyM730RSTz5Tr3BoBwA4QGchY4M/kNhlxnWE1u1cX+G8Lctrb/NmbpSQH/kb+nVtEfbNLnDM4uYAUkaXl3oojqPUYpojCmGbX1Q/+IUqYPUoh3XCtmmUr3Ksf1eNj5Jjm2yt1nUFpoNpiIpK96E039cG7/NP75dTcmLXrusit5QJzc16c/Bt10o5qL5bqPZsd+hI73jBj3xf7fbdMANGd5mj//FtB3oAEAS7/4lBWC1MZ92X5w248hFGmHNsB2KYl4kJsIUNh1PEZ0xpN1RAEPSsPlP/c47QrSYuMB0JNMgDo6pp+wD3dVfuiqf4CSHoBPCCi+cPBpgDVOAF9c7uifePfucPSqiHOsgABzABgFd+mM1+/UhtrkgCZyDagdzvjiZJMGjaeDd/jCd3KI34cCfv5NaQtgcIAAIHEixosGCZhGXUHGzo8KFALRAdSpx4UIoTiwcraiTIcSIZCmwQAcDYUeCbRHfaJHpzUqATKS8Fmuzo6FGhQhwczQQQs2fNl1IGyITIJw6eNm3wxElVVGjGnhzJIEIgQgQCRGQc/pTaE8DHk11nhu1YVmPQl2ctDohq9utEHVevmoH71itQt2q/ri1IBsFIODT1Gk3U5k6cvhDH/55M6zASpkZ1HlEC+5VxR8doiToc1GdOmjl9Bg3EjJZwRwVVRbD5g4iORdMaFT+kzfXpXrwzNc/+2ja33YNlROgwY7xMcIu2Gy6/iLq37oZ+5IiQ44cgb4N87KQhdCjiZdyZnw80BIlRHUuQDA1sblD2xOwQh4o/mnRpHD7vxZ8+SdVqFn8IAptY/EFHVnh8KZjXgjP9dpJ7J6khAnLJ3YUgg9FB6BAciGB1XUHyCTQIHmngQVp7Ce5GHiWP1NFIJZEYFCFB8M1H3nycAbDHZ6GN9pCND4ko0H+sCUgHjaUZqFyDLwVZW5ON4QhRkgI9eKGFAKCRkA4lKMRQlhRFOf/emAcWpAcbJ2zlXGeEpGGHfgVV6dOSNxbkiCQ5PcITcypCBZQSttjRhon5xVankOQV2dqAHvkJHKQFlslkhhg6OOVGYQo03Fxz1aXpQZfQMCqppZpqagWnqqoqGWes+iqpqcL6qqylXnECG1rA2qqq+xDSRgqfrFrrrKeeQUaxrLpKQyfgoCdOBMUSmyypx1JrKq/X0oACLcekcUczNmhLg7Xj0pDtqKKsxkYMq3gyrLmjlmvutNfWS+28496b7L7FoqtvvDRcaaaFahh38HEzlYEwcmgogMCnck4aH6ZiRjedCIAIlmhBcazUEpQ9PdkQRpRMUgcjlbBH6Uwjs2n/0SF93NGdCkogeltedAjyh5GNUvnohhp25HKmQvdnNFsVS0yQGwgzlAcCD6xxkhlgNjD1S2oo9EADACjQ9QNuzDixnUhPxBEibCAAYtkAeMySSz+LfPNBjgADSyGS8ImlpCs+9AZSStkRh0v0zf2SzlZkgZXPBA9Nd59mLwZ50Zb+KflDA7Ms0BoKWbCGGhagsYYFJ1EoUHFwoSE6AKznocDYmDs0pMUIhkRBIGS+DfLmfVtkSCXo7eAA2UBSHuJzeywCmmh7hKijk5D7oYccbGDlxSXF4yx75C0fv7TlUmrfkOZnN1QGAgC4UQLqYEJkRqdXdf2VAp+KsGn64EdK/yb3B7lCHSI2hhYYfCxujtOIy1qEMpXRrnvRqxQAYjYzPCwiTgYxnPc4RD0KiOAEgMhdSZRWuQf2L3YZLKH+xIdCgpRPbgaxAHKMIxAEVAgibrCKDhCAAAWg4StqSEAPAXA/AKDPhPs7Wvg0Igi1Eagjg5gD3JKIQERFQhKNKMSeBtLAEfpOSoAbVBsGZ0CSQa+LAIBDIABxAhFQ4IMCHMz4DkI0IwbthFLsHf/uOJEWhqwgNxSIDAFAw45ULTn1G4jrYFcQDzihkY58JCQhychIUjKSBdBCJTPpyElqEpKCSAAbJNDJSI4DBG3oATNGWUlOqvKRWihAJeGxgfTcwP+SmGylJHEJyVfqspGpOAAIvtWHXuCyAAOAZS+dwEsneOAECWCjHELghkxeMpmNZKUul5lMbOKSm63UZi+9qUpxjrKa1iRnJwdwy24eBIYCWV/7CImwBrivIz8MotfAJrYU8i2PR3SIhx6ABvcMwk19eMMW6fi4O+GkEZiQ0cv0OLmO7CERoOHGPJwnlDJ2ZH1/YENrrmaRhPJzinFUqElXmCII1vElfKzdQP4okNCNrnQdiZ8IgPiSBsxPIA6DGBf7icR/GoQOJ8AdeCaynTfFiaSOOhwAzIMeyrSNqBOFiAQLhVARPu94cNigCJqglctJ1HgnLemhzvpUv6nUSlz/TSpBFFBDAEBNaqZTSAIaIIKeggquVuUY9zyksZU65A196I4FQ6hWJWXCRTBaWVVbasaBvOEQYLTDIQzoVJpw9CBkUCMbP6iK72nxrWslYVlhOtkD4nGoku3ISx0YpuEEEWJA7Sth/zo70+b2IEalwJp6WxDDEAJF2OGtXztiCANkYDKZUGFqG4IZwJXoDn34zgWRi8Gi7sxIemDbHI+7WJiQVrisnUh4T/ta1wo1abrtyYSKo4C93ha3lmmrYiUn2DcmdyAeQwzJkHvfjjS2Dhm4AWT9ud60AoAPi3CTdTUaYKCUEY1y4GBWmlij8uY3unLk8IDf++Hxhhi6IjZI/2yDmiX4XUUHaBikfQEgqnj1a1b/0ta+NmEBNgQBXqYaxQJYsqtl0YtanXBABrAojHxd68b2CtgZJqCCJIRmEeFIlpOxPABkeUIBHGxjIFoBKyZTK8v8gjKyaBywGo85zUVWc7zMLK2ApRilWdIa1mJs3taOVMBnWeIf+HvaN3DHDmOMqG5v8iKVkZel7X1IRY1R5cRSrCdlaAIUrCcgtl2VrCcuSHr3bD6oetjOlcZvndGaHKjpEAH71POc5rTZ5MLho3pwIXElDFg9StW5oObwrEsMaZmZCAbIcPRDPrvGBNwiuAtla6l/TeI5hbq/543soyGSavXeOX4Ri3Gsv/8S7I+QQW2c7tMg7nAH7Pa5TFUsxGNHDG3d8miChKMTsgsyvY+2Rg8Q6CyDPb1g9II43KT+NLfZe+3MmXZOEBkOX/VsbT6f2lIeIolFclAi3im8d5SwRB0mUZntCfzR9dbqhvMNAGV3EBDB3e5qK45wJU0baNnuY8kX7pBtizo4CciDxAsy4zebS86zStUaTpAFUVBrEW1YgLDGZXRYySoblWiELC5ggmKRGctEBpipiEFsVphCE6rqur++ToM16OGjWSCFFjZxKjJsOV5ot7Han2x3N4Od6OO6+9HXHLCp04rODbevBSzQ6leDm8TjDkRrBH2QPUCRBOL2cyQaup7/lOacZSdnyqGlzVY6IGKNHnT2BQFOcJW7ELUzn/jq8StrP/vm8Lj1dtANPu+TyEUQFjFsGg46+55QYpaTeG7MsT2bz9879ohTQPVE8IfvjlT1nTbxwK+ffZwnv/Xb3y2JeQ77oINK951/CBwAo+HOqBtFw1cuJK7IAYi6XsEW4ZEAUP5sjfhBEFYB80ZxWLWNm83pnGzt3+sJW8eN2qUk4ES4gQWIwITkWePhl1OVGwK4wkQAXyIkXLtZBGTA23pQG7BxFR8QGx4sQ+gFXLIBAoYJwhBol/WZ1e7dHMklIAnWHOtxH2zZHqiggQhEIACkjsSZH/ZBhCCIAEnQRrrN/4GuKeAHPoSiWcLIQaHzHaF2LA/K5WBDfFX1sIEc6MHGzBrMIaD9GaC8RZsHXuH3HeACel8POuBD0Nb91FeMDV3fSV3erQonDAAblMKo9IsmlEMaRIOqsNmrGN02gFwtzAKqoFmc7eGofAItMI8KmF2sQKKpbEII/F8VMB22SKKN1Z25AF4iimLg7Z3gwVkp8h2OrWLRoSLVGZ4cOsQaiMAt3iLj2ZcRnqFB+MEJnEATrUUTPmHP7VpBnAcW0d8aah97UdekqVjA0YELdpAgnJt47cYM3qAvMmD92aAbsmAbSqPMjSOK+SCoWMVV6FQROl7F0EHkJdxhdaBq2V/8Ff8CJiSYqjljFLpNdSUCpe2j8QRC9E2f5CEPhQlgCZJYtVkhHHIeDl5e+KGjpqBBCewQBVagGpYWROhBxtAR5d2BcYVjxRkCJoigPpoaP1aaZR1GHxgjOWoQFLCGHIDQG87ONkrXQuJXQ/YiRJqjQIIfqlEkbpnBXPGiOz4EILDBrRnRIrzJCgblhJmkCKLhfvQECujCSmCWOfYfz1CAFQBdDVafQu5gPf4kOMYkDW7k+CEjULIQUfaVCHwbUlogedQaG6zfSr3Br7DbQ46UMpxkI0DCW9JcRzjYzAyDX9qgzpheowygDJblWFLcSnpjYTaa7EnkUNaiRcxl0OHhK0b/oqpwwhGcACcU3ii0ASFg4pmZSycwASxYwjb4nbaY4qhogimABiFQwz/IYuGtiidUAQf9QQjIXbW4Ypn5JquQ4t8hp9fBYnNCZ2i2onTqXSxWJ7WIn0N+RdMgjGfOhBo8wA4BkuIhAPtIpVoKJUHAY6DVRiKkAT2mZXmc5AfwAEPezCFUVwXBkdBQ43CKYRpiYXzkZIB241+yoXyi51VmplmSpLYRJfogwPxghQ5lZEOoY6fQpUZ8DkEEUno6qFtCnhxAxBuY0khaJVVaQiYQ4MERxB6A0UsipG4QJEiF4UFi5vkJCYEuaI7yIFpapYKKHltup3omoHaGBU0RxBB1/xTCJMxL5IHU1JAZyBU+NaOP9qNHNmVnPF1UHihBUGUjjByL2pFAIOabLCZHSgWNgqFNVqZbboZk9uhZimOCWik31ukxFullAsCRFkQJNEAZ5BmFWKjEmUGXlADrNA2iHiWRgqh6AoIIaGlDvGci+GQyVmWaDulYIEVoNN+EvQRBZgGbfmM/ZsaOCqmAWqYZ4mlb3imQ2umnDmmfEoQOmcEDPIBA1E/UkN9ABNKfEgTUGIQiSAGxFquxHuuxDiuyLiuyQkABEGsYZMEQMCuxIgMeoEIvSIGyUiu1buuyxt8GOECzPiu3dmu5UmsBQIAPDIoA6AI0nKsUOCu8EiuNZv9BEzzAvCJruuarscorvxLrv0HAvxLrvg6svw6st/JrwSLswBJrwubrwv7rw87rxMLrwUpsww4FuearIhQEjOkABeoAo8aYGyjSrw4ElAprxlbsuTorFugAj3HrCwjAHDyDw64ss0ZAkmFCCyzrxfIry3IrNCxD/mEWv/7sskZBE4hqTd5sw0ZsviKtxQ6AwA4s1M6r1MJr0HLr1VIszj5t1TJsw24ttWbtuZItsx6TxBaEAuwTyBLE2/IqGuiAG+SBBTBE2+aBDoglrH7oRahCMN6o24RR3ypUJIBcPuppneZnGiSBOnSp4g7EmsoB6nGhnF7EqabcZKrqj1LmlSL/6KvmaawaKUWuwd42gA4QkVwZKq8OBBrwFJioQQOYAaFa6kTQQQKcgOAeVhwE6WkZgos8AjMi2jieoFL0AR9ApkFMbpsWLqoaKE7Gaap66VpGZIuyaqMSL/bOKkEYjBsEUR6Ywfe2LoMiDgU0wY3yZRsYo+6dpIqW6s0BjpvgAbspr0AwL/W6ajnC6fXCb+jiqPWS6Z6+n6zGJfmGie06BDwiAI5Q3hysYLhlQiMMJvTO6Y4Myh0A5POehn+Oqufqr/INqPRWsKPqpA4KMPYSMOly5gE7BGhaJ7WUAbuYGT60wRaw5iPGCzpYgiwYQCdoC+H5WKmcQhyABiuIy9k5/+esvMItLA4pAOJ0Rud1Fh1z1qYS4x12JottCnEeWnEWz5losuK4cG8Ll99ZweOI8kYcwOfnOoRJhtzw+u/mbMdhaDAI/6IgcBAU/EKVYq/9BmD/7u//4lv5kuoHl7D2DjIZlzECnxQ8AgJ/EkQftEHvtvFBUMIEz4BmYkgczC+aFuhBfJXpieGYGnII58gI36QFu6klr3L1DvAmr/CeMnIrIzI8amlaENr6cm5DRMIk4GP2ZtdXCIFhZHBAgvBX8cwJXGOmJuAfN0bmGubl+i2PBrAp5y8iC/NmzjItZ7NUZmk2AsAbzMEcHLNKEkQlFIIlQJQKawSJdEclrxaNtv+RXpZy90WuCAfyKWMzKA+y5Vrz9NbyQSxyNwdHAgsEOGejA0OunToCIxRCFQazjP7e29hBDjxKB1MuPvMy6ApyPqOwHHM0K7sySZtwIQd0SQ+0ARd0T7wwtbDZFYhACMydqwQDsESxqhRBHdTCD5cKIq5KEH/CJN/BJdLATycxDXDiGsWArmCxGHvxFEtdFV/LFtP0F89KVZ/KUWu1JtImDAOxch4iLXIzSztvM96ycxxCG/QBUTl0IyCf7zbzQbyzd5h1aZiBMguC4IazM+8kIIO0R4v0K6dwAR4yNU+0LGNvWcc17KH1RSxDGsRze2FCHUhCSrbq6HYMaMDJOXv/VvW0ETbus0BXMwmnXiqHND+TNmHrc2ozdocl9iAvtl1P3CM7BC1EttC4NVwfNl+jxCIUUDb3n0jIQQn4dV83qGmz9ka3tuYO6T/DMnJ3NvmstGz7s2+BoUPYASp4Q5RQtmUzdzPzQTFL9oe2XQcB6DPvaXrzL2CLdkqrtnUr93u7tj3HIVnLdi+icXa3wQvQnkBEAiO8tWFr81LVtUhTIxuAdnOjtDcveGl3lXwn8oBvcHy3N3hjtoQL9s5Rd3VPhEu3JqmswREMwKukQBsEQxCLNQ0UQSFMQk+DcSyOQgqYyD589ahwghas0R9QAVJHdRdT9RUPWZxNNb4E+Sle/3WbIflvUudT23hyKvmqEHSHr7ZAwMEJ5I9B8KUTvjaEGMIvR7SGN8Q+uABTRQodfDYzm/Q0S3c/B7aOnrabjzaFT/hsE7Jzx/KeSvmU0zlhWbnuHsQ4P3Akv8QMqHMcg3dBpcEWmLPciHJ1oF6bu3eDSzODJ7eFL7ecOziVX3Omi26GXzifcvieTzpcycGfZzk5axZyUTYmoFBBsQQ0+NmZJ7hed66k8zalPzh2RDMA63qd9+R9nvCau7aej3qnJ1X1hHagj5FTGYIlFAIBxNGrg8ys6cEzafQ9Z7YfG7epwvmtszl88zmGh3uY4/qg57moG7trS8QS6aU4pzpiT/9EJqizIRw0AEy7qp+EHywlBUzDXqt5pYP7nH/7rnv7mw4ysPNkwSXlNis2rwbqQGhNHwvEh0uLFohAHqiKJnDDHJyCVVOLAdQBJgTiVQNZ8Hl8qaR4KZACVgSCUXc1WEN5j+vhkBv5qmR1yoc1V6tik780zOO0kz9nzyeLlG+J+0D8AeutGcyP0t+twBNECTAloMO7NkOEsxcCXFsqH7gJZ1d9F+YxGwAC2zy3KpO6nQd8wUe416v3wiu8sKN9nRO0GUCMWHbJA5yn3LLOQCDA1Mzu0wuEH4T91Av6pwuEI9B7nZfFUnV9hu97ggPor3P7tkd32l+6tiN822tq5if/YH1rxCIX0UCUAa4CQAKQrxtwTSEJEf78vZXbVEEsO6ZDQmX/vV+lRHfAZG8TCc8gQPN6OrkfvLifva9zlsFj+nxreoVz+vH7frxvL0XWz9L3UCDBGPnNfR7kQQIwxBCBvl0jwAmswkHgAeFf/kDgBGHS/oA53RycaGbrwRpZx7ELf9mbu/yjdvSqffNj/tuvavIDBACBAwkWBCDFiUGFCrUsdDhwQMKHBhsSRKCgTAMLAMyYEYigzESRIwd2FGhShMAyCAx6cPISZkyZL79kUeVSZgoQRGbKLKClp5N2jDaQC4ozaFInLm3cEcBAqU+gToZEoZCliaqoS7cG1VKg/+vMn2FnIiX78utZmGPVOikwAGzbtG3ZtjV7dq7dti/vks2rtm/YwF3rAt7rZMBUsh4KgvxYxiQAxyQpO8zDEoACN5LXAGjgsWBFknrY0AEgWqCdNntEIlToqJAlQw5RV85BqE2iN5URwkHEhoIeyrUpO5FSeaBr5AKJkzS+/KBE5FIGHF/+fLny5c1HYt8O/TR478i5iyw/UTt58BHVEywB2oKaMg8EJgB/X4GCEjrQAMijw4z4KKKMDhGEC28g1VhrTbqBIClEkonOW+gNO9KwYzfkymhCBAQOHE4866ZrsLIJHRqPsvRSrA46FElSEcQWRWzvOxnBM3EhHBWCkf8kHQ1ir8SC0ECghAcUEEiHIku47741OhtIvv4GHMkPNhAZSLQ4VnuRREzqgMQ85BZpgxASlvNDDhGaIAM6HwtycSQeR3KTIDgZhI66GYvTk8sbQ/SzzT8DHTQ7EmNcDshDCSpDjUWfZBLSMEWC44Q/CKoojjQOSVE6Qx4pxJE5KRtkjjbiQJAkNEX4AyxAr+MzTkN7FHREPFl8FU9ZRbWRUBqRs1PSGgt1FblEZ40U2UhxlOMEOC4FYJA0TuVUIEMYYSTUXSd6o480+shQRzrSlMOP6IitDNiH5Az2V1jvzO7WdnM9d096j8W11yDnzZcyY7VNFuDlLqGB4IINJvj/EjY8ObiCYNrg4uCIIybjDBq0aWSHTiTeuIKNDaamDWNQMLhjjwneJM0HNimYYpNNLtllic8gI2aJW645YphxLnjmnQ2+2WcayBiA5qBp6NlooIPW2WekjWZ6Z6hxdnppowmWumalfcY6Zn/ZDRjsfxUiQ4RADGKmDTsKhe0RXw3iA7dFplxIVXILWldCWnnT9et6h4XX3YnSdQjvh+gcaHDa7O0u8Lz57fPxkbx2POzKKVcIDisNesMYPPCsoQ5MhDUokTbwyDA0usct16DCFee11shFSnxHvtWNF93GCbfdcL31HT33xfuGHPh+eZ/b8uSRN+gEzAoiBATUK7vh/8vH9yh10xwNUhUB1msXXnDdF3Jde9j3tlV8hWhv/fjy8S3+Xnllv/z8+R+avHfl9X92IUAocLYgqhECdB4BCx7QKxHekh7yfMMGBLBJXe1jiO+I5za/xW46uLtg/eDHOPDl730WjB8HRSg5CWJpfylEVUECIQLTFGRMezjcp8xxwtQN5Hp3GESwBMGGE0AQPTbkXwipZb8TpY996DNfETs4OyQuT1HBM6L7MFhCkeDvdSpU3sAixgk2cNFgU0hDB2jANYl1AgmM0IbWolawaKShHJqoWcdKQQEKNGBnbMSZGU1GtTxWzGp89JgfcabHmA2taEEjZNYA+TSrHS2RVf8L5CMXOcdHCnJjhowZJiWGRSpqsXLN+YPzcNgGua1wItZixGzIN8Ec7pAkHkCAlQBYwd/Jr4q3lGIuX6RB5zyRIK2E4i8/mEVcWpF+TETm/YR4OFDqEgCBYIP3BPKGO6iNOSRR5WzM1aYxnS5V46qlMqFJzL81MXz7yiAwEcdOgQjzhkSM4jzNiU4Q8nKExlvmM5lUmyoJwiCEmMMQH+IIRkyCm91EzhtA0IbsjeQ3CAgDeOBJ0F2SsJwePCdvfKlRfIptgxkdnkf3+Uly0tOEJeVnvhBAytTcQXomYtvdhAiAQ7RhAXwgCRnsaDZnKlSlBlkfTYu5kKEGs6YH6aj/E9UZ1De5M5tTVB9UUYnSd9nTIZ6c4ErDhpoeUhMAWloQCgtaiLYRtTLdWgSO/PAHESACgD+tKFnlGauiTrWpK4LqUZOT1KrW06kWDalVk2lLwjIzsFwdCRg3kQU3HAwFaShGzkyGAVk8wmaNjBkKuHEHH5QxZjLIAgLWQLJHatJlnIxYJV2G2pdRMpJ/tBoircZak7nWY6o9mG1fO8naxraNvk2aZrf2SK0OU7H9HAgCLEWQN7ShD1t9jVnHJ0EtYSiqCyHDCShgtnh+dKRM3ahI0zneXu4VqnPN7jHJe8+LtteYGD1sVpuZ3IBVpIfjBAAhCGFSgcy0uiKpkKkE/ysQOABCBIDQ73rlm0/AntTBJIVwa5ZaXvAWVsLz9W+GIxzeIN71R/W1b7IaUiXvDqQPMPUvgAP8ED7MYQ5jZbBApHmCF0r3wu4drF2lKtT0JjVPSzRshy2c2Bk/WMM4bjBISXLc745YuZUqyCHSIOMnA4DFLV7ITcH5ZDj8QXM6HjKTOXxVIwOAr+8EcoUfkmagwteoVP3pT938VzKbGc4KcXKBoSwwRWSBEwY7xcN6WzATFEIMhySuwbqlAo4Z7ApsOMLKUnvaRe8RtrO9tCV/q+nZEq3Tw71kpoUrSaPxNrej9nSpfbZnuvaZIB3pSKMg05HNFCQMZSsIHvp7z/9IUBfP1cSNlfn3ZTYA9M4f7vFT85pkHzc7Tmw+IrST3WY5g5jZy+ZzsImMWF2qQdagCXejtCiCMpy7P2bASBkeNZAEyAGGbdApCK111mDv4Q5zWGDqpNk9Z6MVq3GmtoetPfDbodfgYi4zweO742o3fMwMX4irGVwGHZw7JAAwN7pBmZJYg0YhVhgnH0wpKVWS87oiWQWYkf1vpGK7Tj+GeTsTPj5pC9y83Z62tl/9Xpf3fMIS17OIB7KSgnicnx16QMYDhAAzSMmihPBcmLapzARO6yFlyMIJwPpwLZ/Zzeq1s3hzbHOE59zreOX5kReOYaEnce0AoDgqy5CAi5D/W+kZ1yKtBdQoNOgHeWPa9wQnscr6vQEPW5oIgqcxczU7Hs0yj3vY13z2sm+Y7Gem87XjLvafzr02aOhPA3QgEL6T+5mTUYlLAYAUFrShC4JZQQaUoZaxpMIYxkhFVKIABgpEYTBbCX5UCnOW4SvlL2Qp/mIOk/ywLJ8wcNmL8wmjGMNMPy562cvxk0L9rnD/KIeB/vcPkxjAOATpj9m73xPQH6YvKZ5zmPpILgCqQu3BdIMnSA/l4Kw5U9SvNq/mMK/Igu7ghIzHAk7tFBC5Mi/PGlDZGLAgQK8g1sD9Sk8N2A/q9kcNdAABdODWzEAHdOABNjCqSkf/DAISYCFb/6ZjGdJmIoztQ/5vAJXM4SIQ7CRvnRCQ29Lu2eJOAIEQACGPAgniPz6wMzrwA28N1lJnD9IAlkQCEurgB8CDFqRlIuiAArhu29wOBx8w2y7PBpEsATnK8pbs7cJQ8yhI5wgwgoiQ6JowUOYgukYCNiDBmewAFbxhIgQhwSBQ4XowDWOuBgFx58Twbm5uAdHQCwtOCHlwEIEu4hqRvs5MDk8jEVRMJH4tQugE8drgBfgGDuSADU6sCwPxC39OICgP8lgRcCDxDSeP8ySQEB8R7SJRIIrwEpeDBNJgH2oGjezhanxGE4xhDjTBkPLgCE4gCB6N1WTrGacGuBhJ1U5tGv8V7dOu0WVQLbOqUZG0sdKisWa4UWJ0y7RWzZGsRhd3sTIEoA5FwhIMb+wM4nr07c1ojA36D+J8EOBysBCvjAwF8QDrSiBR0RFpURLbziD3sSAZciLWkR1JggFSkCAeoRESSkfwD5vuEcE+xA0dMhYRchV10B9vcSDZaxIXEudEch4Pcg3/8RQrEQwjsiUFohLsLyELQiNfbiDgYJZuDCSD8utmkuZMUiUX0QAJRxF/EBEBUiGFcgyf8iOn8nviDiJpkhIpoQ4owSkJQksSAeC0sFn4MSaHUhUjDyZzsgBT0uxgcXdacRZLkiXlKgDXIw6xshFhoxIAMVOwrq/wEd7/2jAqG5IqmZIRj9Iwk7ItCTIVBTMxzzII53IIrfIu8dIhwEhiWuADMIuyPMYUJKsbZUAECqC4xBEbTXMbwdFjcMsZrREdfYa2XFPUULOPVDPVaHOQbLM1TS1oWLMcjasyLXMwASAeMa8vq4sUgcgxu7IxybIom7IskZItd2Qp1VAxC9M6IZMNnZPtCHM4ve0sL7E8JKEQEsopj3Mh6CABbEwy07I717IMiXIk3TPIGDMk5fIl7RMxmfM+5VPuglM4nVIrW3CY0FMhxHLBuLMmzXI5axE61dIlr7N1qtNBDxMqH7NBIfQQ8/NB3xM8M5Qdm8MQCmEvG85ADYIMHKgu/ztvRfWTQRXUFXfQRauSJeuMBmf0Oy+0H/3zKgO0IDCzYCwhHcKxYIohDUzBYwpABFbBNzszHWfzSb/xNUtTNntz01oL1KoUNq+USKUUN3ezaXTzN7+0G8k0YnrUR4HuJiPhck60IBDBQO4RRBeURvFTQg1xJS2UOs/wTvlzQ/0zMjlUT3N04gA0TVHp17iSctyUIEjxhTwP8iDVLV8UF9HSKBcTJePzLG0ULiGPLuHQEuWwNg5qVxjVwBz1L22xQ+kUQ70TT6VTU6ONT6eTUGFVQQMVUCeTJdH0UFEDE8pTVEwVAChlLFO1PS8VOyu0T6OzVZsTPSj0OQf1VZuVEv+TNVpz1T1ZdQINNU1FwxHqIBN65An9kiCIVb8klSXRNVNd1U/zdFnfCVrnE1lrlVr3k1mzc04/lTJDtQm5qBMYARh25gnaQB02ZhNO4AhK62CalGG8cUsddmfIcWG5tNC81EqzMdQu1kx3S0ydlDfDFGIxbUqDy2h4dcRaqqU64++cbqskQR5FYicPNB8ptVrpdUc3lST9M0bNcFLrVGfj8mc9VVfPDCLXAGUx4zIeoN1SKP0yowEA4AGYEIUyoQ4I9CGeKwDSc2Zp1l41lGt1VFlpdVrxlV2TI14tdVVxVTt71mbvlSd39S6NDkosAA3WYCM6riDo1j+OJDRGVHT/RuIN5sAOmoMOtvZrrdVD31IWs1VtY5XCZtVxK5VTF1dVpbVdh85t5FYg3AD+dAD1UsgCEMACnlbjVo8iCo8kAlffiKNwA1NxjzVtt9NZa7ZeD3dCIbdsvdZWK7Vxb3VoeTRuPdACQiIyVE+L0MACOsPjNHcgfqAQ2HQk7MAea6N1czdxEVdOYTRncZY+z3Zng7Zyb5B2Lxfu4LaE1sA+ilfvQMkx9DYP+JYgYMEBwsIF2mAC+CImXCELvqD6DgP8euJ/xcL6jK/5su8sxk/4CngvEFgp3sKA/eKBn2+AmQ/7/NeCK3j7LpguJlgwyo+DlYIxFiIlOBdJPld/1mAz/+pOIBTgaaPWINCBJMSKrqo3csfXbY3VTsWWfMl2dpUSd3sYbK91bXF0bG/48fZVl/KAeOlDDejWbkEJDUrgIp5kZUGuLDPloRCEhmu4a6/XZ7l3XotYiLkYU32OjLF3cmsUaM9SXSujaBWASKQkaZdWVGGWwJ5li8+4bXW3fHNYj8VYXju0PtcViNF4jec0jc+sjfXJP8VzW2AwNPL4j3fYiLNXcrcXkTH5cdn2ZjNZaDmZkvm4kxXUZH30PAJ3/gjCFSjAdd/ViwHZkm14jK1XW8N2ks32h/sTjGHXjH2Xce2SX2ENSA9GA+bgFLqIAv5gZEU2Sh92Yw1GYn+GYv9vU0uhsTez1GKduZkjtmMb9pl5ppvPcZsLaZrBdGdKOUDLow/kzSAoJQESlJZvNHZBGYfBV5C9V5Mv+ZOJOJRfeZQrFZ2FkzuojNgA4AROYBV+d4jnmZ/reZctF5fp+YjVeJ8JWZb9+W2JlltNWSFI7pQKglngQF952ZVreZYLeY8DGaLhNZdf1499uaFFuZIXuck2Op0Vgr8UAlVHWlBLundRGpa/97wkOpa7GG17OiB5V6HnNKAtc5hpARXk6GBCIAsWBrSWmdPGmRq/mWCimWXKeUyrmZwxVqy3WqtjxqsLxhzVmtTOuku1+WPP2aYFWic1xSD0QASAiKexNYz/+/mofVp2dVlWiZqmpTKlTVql+Zqhi2WuLbM26BBF41SmHTpfl1p7f5mwKy+zOzV8k/qiEbuogzgXGxsvUSPFFqhwr2SmW1SRWbuXgdqvhXqwYzq0DbmiX/uz9/osm7q0ByJarAwOWBmWC7tSiRs+4zmwXVqvNptySdqzjVq3mZq0sbIingssy7V5Dtu4jXq7/1SHK1m2N5m2u9tdFxq3oduyAXq6aZKLYsEYzvQIAs1j4ZpK43qsuRqSsHqT2pq+CwmbQRZK7Xscw5mt8TuthxG/GVacg4a3qTus2JkgAGGasJe8tdu1xVe5H9qVB/m8bTeoD/myO/uWJ3u0g7nP/7SA5Mi1hYDSryt8uC/8uT08tvP5JDv8iz1ZxB3QvAEbOhqcJrVA/grin7gbxhXUxXlYsEP8nltaxsEbxPU5x2G7kn08IpegDRaIuT77yFebsxfbxvt4uce7yHW8sokatKOblNc7IlEhCgXiN+CZxGv7sNEcyr0cw5ucpZmboqM8Qnf8u+OcytkRSD1BBB7rra1ZwPdbvw9dGhe9YgFcY6+ZwPM7wOsb0hOd0Qc8ZLM60jHdZAIdlEiYI0KXSBjoBADByMdcy1W9z0cco086yZ+VyW9cyZHasGGZzj8bTUvg1jokZZ8pD0L3JKz4uwChWFf9tnlczLt8pZVq1sFcw//9/Nb9OteNukdLwAJAo2m1yGgv4yQwwgSza8XndMvjvNwT+89fHd1dncPvnNbr3NbJHKbtvKYtyA0UIDLMjY71B3nRQG7dwAywfX2jKnNarrhZXbTl/MMxe9lfseH33LmnvZKrPeEh0ugiA98RgD606AEaICN0oN28vSAUQQqkAAGOoORTXuVXvuRJnuVfnuUhoABgnuZT3uVrHuZvHudjfuZ3/uV13udTvgAgIOhXXuaLfuWBvuiHHulT/uibXgogYACIHuqZHuqfHuqVPuitPuuhvuW9Xgq4vum13ufJfuexfuzBHi7GPm+VOD8+9+K0CODVzQKkNg82niBIvgT/SgPpzR7n0b7vwd7vax7wi37waV7si77wg/7wYT7xg37xz37qvf7xfT7yd77xX77yy17wwX7zMb/zvf7ycT7zWX7t+74gZK2l1hfk+UluNeM/8oAiCsQUUz3Z0x20wxveNxyfGd6i0dvM5bnZQRtNTaIMMEIEV0oNbk0NPmPfV+EEWpncEZ7CqX93Y/2zdb/G3R3acTzi5V2pfd+NAfTcBCIPzMANwr0JfQ/OE/7cQfv9td+o5b+Muf+fs//J8f/2XZ34AcIJgIEECxocqOWgwoUMGzp86DABHYgHE1I0KEXgxYIWNyL0SDAjyI8jnUgZKXJkR48mUWr0KGXASZAt/0GmBLlyY02cIwHkvLjT40+KQyHeFNpzwEuiPZs6dXiJhtSpVKtWrWA1a1YyZ7R6nYr1q9ewYrd2LZuVLFqqZ8isrcr17VW5bN3SpRH3LpkBdum2vYv37F21cv8CJvwW8VrDgwHTUIw2b2PASpE+vYzZZ8+iD49u5OwQdEPPF0UzDHqRNNOSM2EuTS2TtcvNPVGXpi1bJW6br2+PrPw5s/CmphcWV6ga4vGKPZM/XG7QttHeq2m23uh8dGzrs3Xn5umde3jLvHd7BO57uPr05F2bD94dvHj343VeT02983aW9ylmbwhdQdIp9x5Q/VXXHnb5PZfUgsatByGB9eFXIP+CClYI0YAO/cdQgARpOJqDDMV04EMgjihih7WVyOCEFJ2ooovTYfgQehZGiCNHNG6Y4oMydtajQh4OBCNyQTL33YU27WdffAkauCOAK0YZY3k/OmSjhDluSVBUhzkmGV2QlTWmWGHKVeZXjMl1ZmKOrflWm5HxBRica8mJVppe2bmWnlr5mRWfeToGqFV4kulYli1yyeWQmjkJn3z0SdqklZRCaSl2TGI66ZMvshgalQsVKaSoRpp6kKKhMtooqhgdaZCjjnLo43xKXvoppP5tmmumkfLnqo5J/koshVc2pKqUrG4pa3OwCovrjMeeBiqKwX5Y7UK0HkTisP49S5D/o6QiGa2J2dbqqbTlYvmso8uyV+y315LkK7yc3pquuboaxWuG53ILLr3ATotupesqW++NFCVb5bsQNruvlvnyOC8A4xa0LbkDdwrbv9F5jHHAj9oar8QGT4wwx/Yu3K7DOI4Bc8wyz0xzzTbfjHPOOu/Mc88+/wx00EIPTTTMigygSNFKL810004/DXXUOQ8ACtAuX4111lpvzTVFoQwQStdij0022QyXjXbaaq/NtkFfh9123HLPzS7ddt+Nd95Ova13335vffbfgg9O+NZ8F4544pgFLrcabrSNRhlqjFRGGctGXrnlIK2hOaORTw6S5E6pUQYajB7OKucjkQ46/6OcV976RaSbzmoZa4y0xu1Nfc4q41uWIcLjALghQucNrVHCQGUgwCoaCBgP0Ro6mIFA8hvpUEIJOtC+0RoJQO9QGRaYQb5Ha1Rv/UUIrI+ACBvlMX313Y+PQAMX5cH8QPCbYUHsCqmRgII4D3wNsUYorDES/IFEAQooQf820oAHmEEHwvOIAvKnPgWQj4AMQcMDNKg7ipSAfd+THfYUoIONoOGED5BdAAeihvHpIA8OGWBBSmAGj4SCHlsrgw5SCAAE6EBzbjAD6NaghgY0wHRuGCLpnmcGzZXBDEsczvlKqMKBoMF9WQwiBztogSFuZHk9eZ5TyKg+zXGRIgp4HP8aEsC9hmgPgwi4XQNyyBA3tI8gV/zicOYIEtrhsIto3Aj1MEgRM4KkfLuzQBwdwkhFQsQNChgIAmj4ED2ukYoAON/xEIDFII4Pb8srgRvKMELLIcAM8FPlA/KgQQDwL4riY6UjW6nE9UjSIwAEieMQCRHnnc+PB6llBSkSwyISkyFivMgEKwdMhyhylw0pJBcLyZA1WnKZmcGmBe3nkTK80iOU9OZDEKBB/z3EAkU85kYGeZEyJMANaHCkM/HISIisUZHaXMgu80m35alhfQOVHBBh6UUAkBGNaHxeBNWZGWpe5AHgHGMJFPBIh4xTog1RQx7E2cJ4stOH7pxkNB3/soYPJgCTFGliGdxgAW4qFIPXPKlB+slRCJmTImuwp0fM0MbupXCnDfmoGxIQQn02oAwM9CUcVfgAB6YPIgDMA/7wqE+C8POcxgPo3MjY1OcxlHlmXGj+Glq6Ca5UlzI1SFN7UoKKPsSH5LOAAiD6kH6G76w2bUhMPfLAeuJ1IVNs4mANYk3l9ZUgOG3rU4iKUgskVYUvTCQOFcDOkXjVIWvU60NiuZGgAuABJe0oFUWb1W0OxLMG+SdWA8o8NJjueW8ciBuSV1bmjXWbtFOgenLakLd2EQAKkGsNM6eDKlKEdjGkLBMruRE9giQBoNPBZCEC2WLS0Y6vXUhja7fY/4X09LoPYW5lo1e5Bli3i6iFiBibuxEAZlSjwotrIH2aWlnaz5PS7Gp35YZNM1JPe5PLLQDeyEq0NmCVFByOGvjX3oc0IAHkM+JFegrU7Y0EuApZMP9K2xA98o+8fnWsbcf3QY9kb72TxKyF9/dAhkxRBFEEwIPtCuLhUHJ8hz1IAiRohhwr5IMfplx4D2KBi2r4wtNrcGj/+5Cerni+DLmjk+dqBhpbLoYTZOn/ICy8Q0KZbWhI6hqY27kzH1h3kZOt7tTMOvVgznbxzVzpVEjnnqi5zlR2COkCaWKC8C6cJBZv5tDcZxhmbnJzLrRwXnfneGbO0QrhXKIbUubQUf96IW0O3aVlvOmDqE52i9ai6DA9aeVlTnGsbrWrXw3rWMt61rSuta1vjetc63rXvO61r38N7GALe9jELraxj43sZCt72cxutrOfDe1oS3va1K62ta+N7Wxre9vc7ra3vw3ucIt73OQut7nPjW61uaHH6W63u8s26F3Lk32T82oJdMfhd7fahvo2tvQGzGs0DlINkztz7pKryjwo8dP9FlwfDYJEGN7uwVVEQxGrSHA1hLrhdqPdFguicVMf+I6gywP5GH1my01RuV+N7QMsVz4hrtKuOUTAK0HL8VdTk5IDaeP58tDETi51wbL84VRzTrheEgS+lHSeG+A3uRKUIQ//jhSfDi45xFwGNAHrswANYy68aar8yEj3GzXfKFs4arBy7y2i+4BadsVRtLU0HKIbXs7UHKLB5DH1oekeSsr89TLmmhP7TOPeaonisAG41eDJm3jKt48Z8XkTLkHwJz1ZrnKDPV3qENGIBrV6OW6gDyDhVZvQ7FJebxKN4QNxzm/Jr15wli+IBRDwOOlqMZLQ1KL+yD62Whb59JrH7dhnn3QwHyTFB9aBBq3bRDM8QPbI19uEK+y/BliAIBeUfgMw/IC+58/DV5bbnJlbcO7lrpOmy3T1/9bog+zS0gNR3ZbZ/f60ke7QBgFonG1cOmfmfgCIf/k3e6pngK5WTwyX/4ANSFUF6ICFM4ARSIEVaIEXiIEZqIEbmBnxtjqRth4e+GiBxoElaGsDdUlkAzxjFmQPkWUkKGMWtoIQskcmaIPD1gAiIAIhVX+TRX/V1DmzYxB/plCx02kzqGqMhUiVUxCc84IKITpEWH/gs36yVDwKRWOdNoX+gzn+I4UKdT6sJUB5BoAgOIRkeINpSDcWwIYiADoKoIM6WDrto4MgdlQ6GEBwWIdYqAM6iEIiQF0AIAJtiFQz2FN4GIZyeIiAeDt6KIcF0T59SGE6mDwrhIhBJAJ9KAJSF4fPk4l4SHCaSGMFEYebaIWamEKWGIc3JAJ1JwIWlwA6uD3AE4c01P8+JfA906eDwKeGvag1a7CJJSAC9kM8LfSCwnhmbKgQb+RIaFACeTCK7RM5IvA8FhA8WZZDmTiNCjCDOuBIwKgAwDhEK/SNIqAA0GiMV6hV10iN4uM+wlg6CZBC7fN0sYgGcPh9wPM8cEg+ozhqtrV31miFUteHqDSMmNiE5qgG5rhFLZSD6yY5xENWmxhkO4gGHuWLGak2+JiD2/eEL0iHq1hMozgQH1k8M7hHM0iNq+WJ2ViKzLOSgviSJmk8KRmN7lODe5STb3eFM7iC3qODkiVokRiLVghzxbOTBqEDk1g5pUhjh9g+E6lFmjhPGmmVY/NGTlkGD2mUcKg7k2P/ctyzkCEFdMFDXG6Iku6jkswDjjPIhswliPnzljDElU+4jlhYc+4Dh5OjjEn5hD75lKQjjBiUZbbIk0cpTm6IkAWRg4NoYzu4dNIYl4tJcFtZlFeJmVpDPOCUg3eVAFyniLEoRO7zQ26ViX24QqBZSWmJl4LIdZ/JOaNIPFx3ewBgjc8zmwhwe28EmupoSWp5k52UAGFklklJPHYFmP04mhUEjcR5mEYJPM5pEFtEknB4exQmjN64kjUIPFdnjpkJnldjcqBDcTZ2WiJwOxZHPmdmlhC3QQdWRJj0YJZTROZpOZlIcvZJl1Q0OQ9mBqaTRPxpng0wngVRn/M5PHgUiKC6U58JalushKDzqZ5mMFkm5wb1OUWTk6EKFWQNanuKWX/kQ08AcEeF5aD6Qz6jF54rijVc14dAZBBUpx4xSWzAw4MsiqN5U0SstBAEpx4tWGxTtHE5SqRFaqRHiqRJqqRLyqRN6qRPCqVRKqVTSqVVaqVXiqVZqqVbyqVd6qVfCqZhKqZLGhAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Length-for-age girls: birth to 2 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 402px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Weight-for-length boys: birth to 2 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 625px\">",
"   <div class=\"ttl\">",
"    Weight-for-length girls: birth to 2 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 605px; height: 387px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33418=[""].join("\n");
var outline_f32_40_33418=null;
var title_f32_40_33419="SAECG and VT after MI";
var content_f32_40_33419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of sustained ventricular arrhythmias or sudden cardiac death in patients after myocardial infarction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Percent",
"adverse outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        For normal test results",
"       </td>",
"       <td class=\"subtitle2\">",
"        For abnormal test results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG and ejection fraction",
"       </td>",
"       <td>",
"        0-1",
"       </td>",
"       <td>",
"        31-38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG and Holter monitor",
"       </td>",
"       <td>",
"        0-1",
"       </td>",
"       <td>",
"        27-35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ejection fraction and Holter monitor",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG, ejection fraction and Holter monitor",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG and programmed stimulation",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG and HRV",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAECG, HRV, and Holter monitor",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAECG: signal-averaged electrocardiogram; HRV: heart rate variability.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Cain, et al. J Am Coll Cardiol 1996; 27:238.&nbsp;",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33419=[""].join("\n");
var outline_f32_40_33419=null;
var title_f32_40_33420="Diagnosis early MF";
var content_f32_40_33420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnosis of early Mycosis Fungoides",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Scoring system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Basic",
"       </td>",
"       <td>",
"        2 points for basic criteria and two additional criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent and/or progressive patches/thin plaques",
"       </td>",
"       <td>",
"        1 point for basic criteria and one additional criterion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <em>",
"         Additional",
"        </em>",
"        :",
"       </td>",
"       <td rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Non-sun exposed location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Size/shape variation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Poikiloderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Histopathologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Basic",
"       </td>",
"       <td>",
"        2 points for basic criteria and two additional criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Superficial lymphoid infiltrate",
"       </td>",
"       <td>",
"        1 point for basic criteria and one additional criterion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <em>",
"         Additional",
"        </em>",
"        :",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Epidermotropism without spongiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Lymphoid atypia&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Molecular biological",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Clonal&nbsp;T-cell receptor&nbsp;gene rearrangement",
"       </td>",
"       <td>",
"        1 point for clonality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Immunopathologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. &lt;50 percent CD2+, CD3+, and/or CD5+ T-cells",
"       </td>",
"       <td rowspan=\"3\">",
"        1 point for one or more criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. &lt;10 percent CD7+ T cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Epidermal/dermal discordance of CD2, CD3, CD5, or CD7&Delta;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A total of 4 points is required for the diagnosis of&nbsp;mycosis fungoides&nbsp;based on any combination of points from the clinical, histopathologic, molecular biological, and immunopathologic criteria.",
"     <br>",
"      &bull; Lymphoid atypia is defined as cells with enlarged hyperchromatic nuclei and irregular or cerebriform nuclear contours.",
"      <br>",
"       &Delta; T-cell antigen deficiency confined to the epidermis.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pimpinelli, N, Olsen, EA, Santucci, M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33420=[""].join("\n");
var outline_f32_40_33420=null;
var title_f32_40_33421="Effect of diet on CO2";
var content_f32_40_33421=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of diet on carbon dioxide production in mechanically ventilated patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 394px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients receiving an energy intake of 1.3 times resting energy expenditure (top graph), variations in the fat:carbohydrate ratio did not affect CO2 production (VCO2). In patients receiving a constant ratio (60:20) of carbohydrate to fat calories (bottom graph), there was statistically significant increase in VCO2 with increasing total calorie intake.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Talpers, S, Romberger, D, Bunce, S, et al, Chest 1992; 102:551.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33421=[""].join("\n");
var outline_f32_40_33421=null;
var title_f32_40_33422="Survival in HIV exposed to ART";
var content_f32_40_33422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Survival estimate for HIV-infected patients exposed to antiretroviral therapy, by age group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 436px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative mortality rate for patients who were exposed to antiretroviral therapy, according to age group (patients aged &ge;50 years [older patients] and patients aged &lt;50 years [younger patients]). Survival estimates were conditioned on the date of initiation of ART. Patients who received ART at some time after enrollment had a delayed entry time, and their data did not contribute to the risk sets until the time that ART was started. Patients who received ART before enrollment were left truncated on the basis of the time that had elapsed between beginning ART and enrollment.",
"    <div class=\"footnotes\">",
"     Cum surv: cumulative survival as a percentage; ART: antiretroviral therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perez JL, Moore DR. Greater effect of highly active antiretroviral therapy on survival in people aged 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003; 36:212. Copyright &copy;2003 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33422=[""].join("\n");
var outline_f32_40_33422=null;
var title_f32_40_33423="Endstage corneal scarring";
var content_f32_40_33423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    End-stage corneal scarring and neovascularization after infectious ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_40_33423=[""].join("\n");
var outline_f32_40_33423=null;
    